var title_f20_15_20720="Candida endophthalmitis";
var content_f20_15_20720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58685%7EID%2F73318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58685%7EID%2F73318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candida endophthalmitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endogenous",
"    <em>",
"     Candida",
"    </em>",
"    endophthalmitis with multiple focal white lesions within the choroid and extension of the two largest lesions through the retina into the vitreous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Active vitritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Active vitritis in endogenous",
"    <em>",
"     Candida",
"    </em>",
"    endophthalmitis. Several fluff balls typical of",
"    <em>",
"     Candida",
"    </em>",
"    infection can be seen with difficulty; the haziness is due to vitreal inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20720=[""].join("\n");
var outline_f20_15_20720=null;
var title_f20_15_20721="Patient information: Anemia of chronic disease (The Basics)";
var content_f20_15_20721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/53/19281\">",
"         Patient information: Anemia caused by low iron (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/49/30484\">",
"         Patient information: Anemia caused by low iron (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Anemia of chronic disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/anemia-of-chronic-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H190068046\">",
"      <span class=\"h1\">",
"       What is anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anemia is the term doctors use when a person has too few red blood cells. Red blood cells are the cells in your blood that carry oxygen. If you have too few red blood cells, your body does not get all the oxygen it needs.",
"     </p>",
"     <p>",
"      &ldquo;Anemia of chronic disease&rdquo; is 1 type of anemia. It can happen in people who have a long-term disease or condition such as arthritis or cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H190068053\">",
"      <span class=\"h1\">",
"       What are the symptoms of anemia of chronic disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with anemia of chronic disease have no symptoms. They find out they have it after their doctor does blood tests for another reason.",
"     </p>",
"     <p>",
"      People who do have symptoms might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel tired or weak, especially if they try to exercise",
"       </li>",
"       <li>",
"        Have headaches",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H190068060\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have a long-term disease or condition and get the symptoms listed above, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H190068067\">",
"      <span class=\"h1\">",
"       Is there a test for anemia of chronic disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do different blood tests to check for anemia of chronic disease.",
"     </p>",
"     <p>",
"      Some people might need a test called a bone marrow biopsy. During a bone marrow biopsy, your doctor will take a small sample of your bone marrow (the tissue in the middle of certain bones). Then another doctor will look at the sample under a microscope.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H190068074\">",
"      <span class=\"h1\">",
"       How is anemia of chronic disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on what&rsquo;s causing the anemia and if your anemia is causing symptoms.",
"     </p>",
"     <p>",
"      Your doctor will treat the long-term condition that&rsquo;s causing your anemia.",
"     </p>",
"     <p>",
"      Other treatment depends on your symptoms. If your anemia of chronic disease is causing no symptoms, it does not need to be treated.",
"     </p>",
"     <p>",
"      If your anemia of chronic disease is causing symptoms, your doctor might treat it with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to help your body make more red blood cells",
"       </li>",
"       <li>",
"        A blood transfusion &ndash; During a blood transfusion, you will get blood that has been donated by someone else. The donated blood goes into your vein.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is common for people with anemia of chronic disease to also have another type of anemia called &ldquo;iron deficiency anemia.&rdquo; Iron deficiency anemia is usually caused by a loss of iron from your body, for example, from bleeding too much. If you also have iron deficiency anemia, you might need to take extra iron.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H190068116\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=see_link\">",
"       Patient information: Anemia caused by low iron (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"       Patient information: Anemia caused by low iron (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/15/20721?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17028 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-221.10.40.236-8B04AB009B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20721=[""].join("\n");
var outline_f20_15_20721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190068046\">",
"      What is anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190068053\">",
"      What are the symptoms of anemia of chronic disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190068060\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190068067\">",
"      Is there a test for anemia of chronic disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190068074\">",
"      How is anemia of chronic disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190068116\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=related_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=related_link\">",
"      Patient information: Anemia caused by low iron (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_15_20722="Completion of cone excision";
var content_f20_15_20722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Completion of cervical (uterine cervix) cone biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The specimen is excised by cutting across the endocervix.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20722=[""].join("\n");
var outline_f20_15_20722=null;
var title_f20_15_20723="Finger buddy taping PI";
var content_f20_15_20723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Finger buddy taping",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Finger buddy taping involves taping an injured finger to the finger next to it.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20723=[""].join("\n");
var outline_f20_15_20723=null;
var title_f20_15_20724="Velaglucerase alfa (glucocerebrosidase): Patient drug information";
var content_f20_15_20724=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Velaglucerase alfa (glucocerebrosidase): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/4/36931?source=see_link\">",
"     see \"Velaglucerase alfa (glucocerebrosidase): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8547?source=see_link\">",
"     see \"Velaglucerase alfa (glucocerebrosidase): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9942752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      VPRIV&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11575112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      VPRIV&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10113261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691857",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Gaucher's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10113259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2714381",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to velaglucerase alfa or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10113269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10113271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever, chills, itching, hives, chest pain or pressure, or shortness of breath when drug is given. Other drugs may be given to avoid these.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10113275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10113265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acetaminophen, diphenhydramine, and a corticosteroid may be given before this drug to lower fever and chills.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10113267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10113277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10113279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12332 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20724=[""].join("\n");
var outline_f20_15_20724=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9942752\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11575112\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113261\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113259\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113269\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113271\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113275\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113265\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113267\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113277\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10113279\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/4/36931?source=related_link\">",
"      Velaglucerase alfa (glucocerebrosidase): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8547?source=related_link\">",
"      Velaglucerase alfa (glucocerebrosidase): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_15_20725="Brown macular lesion of VIN";
var content_f20_15_20725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar intraepithelial neoplasia (VIN)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    VIN manifesting as a brown macular lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christine Holschneider, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20725=[""].join("\n");
var outline_f20_15_20725=null;
var title_f20_15_20726="Myopathies affecting the extraocular muscles in children";
var content_f20_15_20726=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Myopathies affecting the extraocular muscles in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/15/20726/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20726/contributors\">",
"     Andrew G Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20726/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/15/20726/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20726/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20726/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/15/20726/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20726/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/15/20726/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most generalized myopathies do not affect the extraocular muscles. However, there are some notable exceptions.",
"   </p>",
"   <p>",
"    Chronic progressive external ophthalmoplegia (CPEO) is a nonspecific term that is used to describe a range of myopathies that affect the extraocular muscles. These progressive ophthalmoplegias include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Isolated CPEO",
"     </li>",
"     <li>",
"      Kearns-Sayre syndrome",
"     </li>",
"     <li>",
"      Oculopharyngeal muscular dystrophy",
"     </li>",
"     <li>",
"      Myotonic dystrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The progressive forms of ophthalmoplegia should be distinguished from the static forms of ophthalmoplegia, which include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Agenesis of extraocular muscles",
"     </li>",
"     <li>",
"      Congenital fibrosis syndromes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26790?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of vertical strabismus in children\", section on 'Congenital fibrosis of the extraocular muscles'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital myopathies (eg, centronuclear myopathy, central core myopathy, multicore myopathy) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=see_link\">",
"       \"Congenital myopathies\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The extraocular muscles often are involved in the mitochondrial myopathies, such as Kearns-Sayre syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/1\">",
"     1",
"    </a>",
"    ]. Mitochondrial myopathies also can manifest with facial, bulbar, and limb myopathy; neurologic findings (eg, ataxia, spasticity, peripheral neuropathy, deafness, dementia); other ocular findings (eg, optic atrophy, pigmentary degeneration of retina); cardiac conduction abnormalities; gastrointestinal motility; and endocrine, skin, and skeletal abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"     \"Approach to the metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other ocular myopathies beyond the scope of this review are associated with generalized muscle involvement (eg, proximal or distal limb muscle involvement) or neurodegenerative diseases (eg, spinocerebellar degeneration, Werdnig-Hoffmann syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=see_link\">",
"     \"Congenital myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=see_link\">",
"     \"The spinocerebellar ataxias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link\">",
"     \"Spinal muscular atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CPEO usually present with a painless, slowly progressive (and sometimes asymptomatic) ophthalmoplegia. The ocular motility defect is typically bilateral and symmetric, and for this reason few patients complain of diplopia, even if they have dramatic or complete ophthalmoplegia. Patients also have bilateral ptosis of variable severity. The pupil is spared (external ophthalmoplegia). In addition, optic atrophy and retinal pigmentary degeneration may be present in some patients, particularly those who have mitochondrial disorders. The clinical course usually is sufficient to make the diagnosis and exclude alternative etiologies, such as myasthenia gravis.",
"   </p>",
"   <p>",
"    The forms of CPEO that can manifest during childhood include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Isolated CPEO",
"     </li>",
"     <li>",
"      Kearns-Sayre syndrome",
"     </li>",
"     <li>",
"      Oculopharyngeal muscular dystrophy",
"     </li>",
"     <li>",
"      Myotonic dystrophy",
"     </li>",
"     <li>",
"      Myotubular myopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Kearns-Sayre syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kearns-Sayre syndrome is a mitochondrial cytopathy that is characterized by CPEO, retinal pigmentary changes, and heart block. Patients are typically normal at birth. Progressive ophthalmoplegia usually develops between 5 and 20 years of age, although it may occur earlier. Most cases are sporadic.",
"   </p>",
"   <p>",
"    The ocular findings include bilateral and symmetric involvement of the horizontal and vertical muscles, bilateral ptosis, and normal pupils. An atypical pigmentary retinopathy (\"salt and pepper\") may be present; some patients have a corneal opacity. The ophthalmoplegia progresses slowly over many years and is often asymptomatic because it is insidious and bilaterally symmetric. As the extraocular myopathy progresses, generalized muscle weakness and other systemic manifestations may occur.",
"   </p>",
"   <p>",
"    Nonocular manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac &mdash; Heart block, sometimes even sudden death (may require monitoring with sequential electrocardiograms or treatment with a pacemaker) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurologic &mdash; Deafness and vestibular dysfunction, cerebellar ataxia, corticospinal dysfunction, electroencephalogram abnormalities, elevated cerebrospinal fluid protein (&gt;100",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      or widespread muscular dystrophy.",
"     </li>",
"     <li>",
"      Endocrine and metabolic &mdash; Short stature, gonadal failure, diabetes mellitus, thyroid disease, hyperaldosteronism; hypomagnesemia; and bone, tooth, and calcification abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal &mdash; Renal tubular involvement is rare [",
"      <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=see_link\">",
"       \"Renal involvement in the mitochondrial cytopathies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory findings may include elevated plasma lactate and pyruvate concentrations. Skeletal or ocular muscle biopsy demonstrates defects in the mitochondrial respiratory chain and \"ragged red fibers\" histologically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oculopharyngeal muscular dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oculopharyngeal muscular dystrophy is another type of CPEO that usually has onset at approximately 40 years of age, although earlier onset may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Most patients are of French-Canadian descent and have a common ancestor from Quebec. In the French-Canadian population, oculopharyngeal muscular dystrophy usually follows an autosomal dominant inheritance pattern with 100 percent penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/2\">",
"     2",
"    </a>",
"    ]. However, autosomal recessive and sporadic forms occur in other ethnic groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=see_link\">",
"     \"Oculopharyngeal, distal, and congenital muscular dystrophies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characteristic features include difficulty with swallowing, more prominent ptosis than extraocular muscle involvement, weakness of the orbicularis muscle, and cytoplasmic inclusions on muscle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/6\">",
"     6",
"    </a>",
"    ]. The diagnosis is usually made by the family history and clinical presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myotonic dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myotonic dystrophy, another systemic myopathy that affects the extraocular muscles, has two forms: congenital and classical. The congenital form occurs in infants born to mothers with myotonic dystrophy. The infants present with profound hypotonia, facial diplegia, feeding problems, respiratory difficulties, and skeletal deformities, such as clubfeet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classical form of the disease has onset in adolescence or adulthood. Ocular findings include orbicularis weakness, myotonia on lid closure, ptosis, poor eccentric gaze holding, slow saccades, sluggish, miotic pupils, blepharitis, dry-eye syndrome, low intraocular pressure (hypotony), lens changes (eg, polychromatic cataracts, posterior cortex star, posterior subcapsular cataract), and pigmentary changes in macula. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link&amp;anchor=H7#H7\">",
"     \"Cataract in children\", section on 'Disease-associated'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonocular findings include frontal baldness, testicular atrophy, cardiac abnormalities (eg, cardiomyopathy, conduction defects), narrow hatchet facies, and slack jaw.",
"   </p>",
"   <p>",
"    The EMG demonstrates myopathic potentials and myotonia. Muscle histology may reveal internal nuclei, type I fiber atrophy, and ring fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Myotubular myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Centronuclear myotubular myopathy is a rare X-linked congenital myopathy. Male infants have marked hypotonia and skeletal muscle weakness. Respiratory muscle impairment leads to respiratory failure. Facial weakness, ptosis, and extraocular muscle weakness typically occur, and impaired bulbar function contributes to feeding difficulty. Heterozygous female carriers may present with limb girdle and facial weakness. A more common form of the disorder occurs in both males and females and consists of relatively mild weakness and hypotonia that may be unrecognized in the neonatal period. Myotubular myopathy should be considered in the differential diagnosis of any infant who has hypotonia and either ptosis or ophthalmoplegia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=see_link\">",
"     \"Approach to the infant with hypotonia and weakness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=see_link&amp;anchor=H17#H17\">",
"     \"Congenital myopathies\", section on 'Centronuclear (myotubular) myopathies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar clinical manifestations may be seen in neonatal or congenital myasthenia gravis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/9\">",
"     9",
"    </a>",
"    ], a disorder that must be excluded. Administration of an anticholinesterase inhibitor results in improvement in symptoms (eg, oxygenation, ventilation, or sucking) in infants with myasthenia gravis, but not those with myotubular myopathy. Muscle biopsy in infants with myotubular myopathy demonstrates predominance of small type I fibers and centrally placed nuclei. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link\">",
"     \"Neuromuscular junction disorders in newborns and infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the diagnosis of CPEO can be made from the clinical course (painless, progressive, pupil-sparing ophthalmoplegia). Pain, pupil involvement, acute onset, fatigue, or fluctuating course suggests an alternate diagnosis (",
"    <a class=\"graphic graphic_table graphicRef76783 \" href=\"UTD.htm?20/16/20748\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Examination of family members and a complete family history are important because the inheritance pattern can provide a clue to the underlying etiology. Myasthenia gravis should be excluded, since a \"chronic, fixed\" myasthenia can mimic CPEO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CPEO should be evaluated by a neurologist and an ophthalmologist to exclude other disorders that mimic isolated CPEO, identify systemic diseases associated with CPEO (eg, mitochondrial disease), and evaluate for cardiac or other neurologic features of Kearns-Sayre syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of patients in whom a metabolic myopathy is being considered may include a number of tests (",
"    <a class=\"graphic graphic_table graphicRef56365 \" href=\"UTD.htm?10/4/10317\">",
"     table 2",
"    </a>",
"    ), not all of which are necessary in every patient. In patients in whom a mitochondrial disorder is being considered, serum and cerebrospinal lactate concentrations may be elevated, but this test is neither sensitive nor specific [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link&amp;anchor=H400795568#H400795568\">",
"     \"Approach to the metabolic myopathies\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Muscle biopsy may be indicated for definitive diagnosis of Kearns-Sayre syndrome, myotonic dystrophy, or myotubular myopathy. Characteristic findings are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Kearns-Sayre syndrome &mdash; Ragged red fibers and evidence of cytochrome C oxidase deficiency",
"     </li>",
"     <li>",
"      Oculopharyngeal muscular dystrophy &mdash; Cytoplasmic inclusions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myotonic dystrophy &mdash; Internal nuclei, type I fiber atrophy, and ring fibers [",
"      <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Myotubular myopathy &mdash; Predominance of small type I fibers and centrally placed nuclei",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Electromyography (EMG) may be helpful in selected cases. Myopathic potentials and myotonia are present in myotonic dystrophy, but the EMG may not be diagnostic in early cases or in cases isolated to the extraocular muscles (isolated CPEO). EMG in other disorders may confirm evidence of myopathy but is not specific. EMG of the extraocular muscles is rarely performed except in institutions with research interests.",
"   </p>",
"   <p>",
"    A number of mitochondrial mutations have been reported in patients with CPEO syndromes, and mitochondrial DNA studies may be helpful for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. These tests are not universally available and usually require specialty laboratory testing.",
"   </p>",
"   <p>",
"    Mutations in the POLG gene cause many of the inherited mitochondrial diseases in children and can produce a diverse group of phenotypes including autosomal recessive progressive external ophthalmoplegia (arPEO) and autosomal dominant progressive external ophthalmoplegia (adPEO) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CPEO is usually made clinically. Neuroimaging studies are performed primarily to exclude alternative etiologies for ophthalmoplegia.",
"   </p>",
"   <p>",
"    Cranial magnetic resonance imaging (MRI) in patients with CPEO may show signal abnormalities in the brainstem, brain, and thalami, and in extraocular muscle volume [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one study, digitally measured extraocular muscle volume in subjects with CPEO was reduced compared to control subjects (215 mm3 versus 366 mm3 for the medial rectus, 202 mm3 versus 365 mm3 for the inferior rectus, and 269 mm3 versus 425 mm3 for the lateral rectus) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/20\">",
"     20",
"    </a>",
"    ]. This finding may help to distinguish CPEO from other conditions causing ophthalmoplegia. MR spectroscopy may show elevated lactate levels within regions of brain signal abnormalities in patients with Kearns-Sayre syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend obtaining an MRI of the extraocular muscles in all patients with CPEO, and MR spectroscopy in selected patients (eg, those suspected to have Kearns-Sayre syndrome).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for CPEO is supportive. Ptosis surgery can be performed in severely affected patients. However, extreme care must be taken to avoid overcorrection because of the risk of exposure keratopathy from the ophthalmoplegia and loss of Bell's phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Bell's phenomenon is the rolling up of the eyes when the eyelids are closed; it typically occurs during sleep or with forced lid closure, but is lost in patients with CPEO. The loss of Bell's phenomenon in conjunction with postoperative lagophthalmos (ie, incomplete eyelid closure) after correction of ptosis may result in corneal exposure, placing the patient at risk for exposure keratopathy.",
"   </p>",
"   <p>",
"    Strabismus surgery can be performed to align the eyes, although it is not always necessary because involvement in CPEO tends to be bilateral and symmetric. The patients who do not require strabismus surgery tend to adapt to their ophthalmoplegia by turning their head or face to compensate for loss of gaze function. Such patients can be followed annually by the ophthalmologist. They may need special accommodations in school and may have activity restrictions, depending upon the presence and extent of associated myopathy. In addition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have cardiac conduction defects should be referred to a cardiologist for evaluation and ongoing care.",
"     </li>",
"     <li>",
"      Therapies that have been tried, with variable success, in patients with mitochondrial cytopathies include the ketogenic diet [",
"      <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/24\">",
"       24",
"      </a>",
"      ], coenzyme Q [",
"      <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/21\">",
"       21",
"      </a>",
"      ], and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/17/43285?source=see_link\">",
"       bupivacaine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?20/15/20726/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic progressive external ophthalmoplegia (CPEO) is a nonspecific term that is used to describe a range of myopathies that affect the extraocular muscles, including isolated CPEO, Kearns-Sayre syndrome, oculopharyngeal muscular dystrophy, and myotonic dystrophy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CPEO usually present with a painless, slowly progressive (and sometimes asymptomatic) ophthalmoplegia. The ocular motility defect is typically bilateral and symmetric. They also have bilateral ptosis of variable severity, but the pupil is spared. Optic atrophy and retinal pigmentary degeneration may be present in some patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CPEO usually can be made from the clinical course (painless, progressive, pupil-sparing ophthalmoplegia). Pain, pupil involvement, acute onset, fatigue, or fluctuating course suggests an alternate diagnosis (",
"      <a class=\"graphic graphic_table graphicRef76783 \" href=\"UTD.htm?20/16/20748\">",
"       table 1",
"      </a>",
"      ). Examination of family members and a complete family history can provide a clue to the underlying etiology. Myasthenia gravis should be excluded. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The laboratory evaluation of patients in whom a metabolic myopathy is being considered may include a number of tests (",
"      <a class=\"graphic graphic_table graphicRef56365 \" href=\"UTD.htm?10/4/10317\">",
"       table 2",
"      </a>",
"      ), not all of which are necessary in every patient. Muscle biopsy may be indicated for definitive diagnosis of Kearns-Sayre syndrome, myotonic dystrophy, or myotubular myopathy. Electromyography (EMG) may be helpful in selected cases. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy for CPEO is supportive (eg, ptosis surgery, strabismus surgery, referral to cardiologist for patients with cardiac conduction defect). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/1\">",
"      Carta A, D'Adda T, Carrara F, Zeviani M. Ultrastructural analysis of extraocular muscle in chronic progressive external ophthalmoplegia. Arch Ophthalmol 2000; 118:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/2\">",
"      Barrag&aacute;n-Campos HM, Barrera-Ram&iacute;rez CF, Iturralde Torres P, et al. Kearns-Sayre syndromes an absolute indication for prophylactic implantation of definitive pacemaker? Arch Inst Cardiol Mex 1999; 69:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/3\">",
"      Fromenty B, Carrozzo R, Shanske S, Schon EA. High proportions of mtDNA duplications in patients with Kearns-Sayre syndrome occur in the heart. Am J Med Genet 1997; 71:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/4\">",
"      Katsanos KH, Elisaf M, Bairaktari E, Tsianos EV. Severe hypomagnesemia and hypoparathyroidism in Kearns-Sayre syndrome. Am J Nephrol 2001; 21:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/5\">",
"      Harvey JN, Barnett D. Endocrine dysfunction in Kearns-Sayre syndrome. Clin Endocrinol (Oxf) 1992; 37:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/6\">",
"      Hill ME, Creed GA, McMullan TF, et al. Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a UK population. Brain 2001; 124:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/7\">",
"      Lacomis D, Kupsky WJ, Kuban KK, Specht LA. Childhood onset oculopharyngeal muscular dystrophy. Pediatr Neurol 1991; 7:382.",
"     </a>",
"    </li>",
"    <li>",
"     Dubowitz, V. Muscle biopsy: A practical approach. Bailliere Tindall, London 1985. p.380.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/9\">",
"      Kim JH, Hwang JM, Hwang YS, et al. Childhood ocular myasthenia gravis. Ophthalmology 2003; 110:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/10\">",
"      Rose LV, Rose NT, Elder JE, et al. Ophthalmologic presentation of oxidative phosphorylation diseases of childhood. Pediatr Neurol 2008; 38:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/11\">",
"      Campos Y, G&aacute;mez J, Garc&iacute;a A, et al. A new mtDNA mutation in the tRNA(Leu(UUR)) gene associated with ocular myopathy. Neuromuscul Disord 2001; 11:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/12\">",
"      Ishikawa Y, Goto Y, Ishikawa Y, Minami R. Progression in a case of Kearns-Sayre syndrome. J Child Neurol 2000; 15:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/13\">",
"      Marin-Garcia J, Goldenthal MJ, Sarnat HB. Kearns-Sayre syndrome with a novel mitochondrial DNA deletion. J Child Neurol 2000; 15:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/14\">",
"      Saiwaki T, Shiga K, Fukuyama R, et al. A unique junctional palindromic sequence in mitochondrial DNA from a patient with progressive external ophthalmoplegia. Mol Pathol 2000; 53:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/15\">",
"      Seneca S, Verhelst H, De Meirleir L, et al. A new mitochondrial point mutation in the transfer RNA(Leu) gene in a patient with a clinical phenotype resembling Kearns-Sayre syndrome. Arch Neurol 2001; 58:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/16\">",
"      Spagnolo M, Tomelleri G, Vattemi G, et al. A new mutation in the mitochondrial tRNA(Ala) gene in a patient with ophthalmoplegia and dysphagia. Neuromuscul Disord 2001; 11:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/17\">",
"      Van Goethem G, Dermaut B, L&ouml;fgren A, et al. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001; 28:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/18\">",
"      Wong LJ, Naviaux RK, Brunetti-Pierri N, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 2008; 29:E150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/19\">",
"      Marie SK, Carvalho AA, Fonseca LF, et al. Kearns-Sayre syndrome \"plus\". Classical clinical findings and dystonia. Arq Neuropsiquiatr 1999; 57:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/20\">",
"      Carlow TJ, Depper MH, Orrison WW Jr. MR of extraocular muscles in chronic progressive external ophthalmoplegia. AJNR Am J Neuroradiol 1998; 19:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/21\">",
"      Choi C, Sunwoo IN, Kim HS, Kim DI. Transient improvement of pyruvate metabolism after coenzyme Q therapy in Kearns-Sayre syndrome: MRS study. Yonsei Med J 2000; 41:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/22\">",
"      Daut PM, Steinemann TL, Westfall CT. Chronic exposure keratopathy complicating surgical correction of ptosis in patients with chronic progressive external ophthalmoplegia. Am J Ophthalmol 2000; 130:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/23\">",
"      Wong VA, Beckingsale PS, Oley CA, Sullivan TJ. Management of myogenic ptosis. Ophthalmology 2002; 109:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/24\">",
"      Speeg-Schatz C, de Saint-Martin A, Christmann D. Congenital mitochondrial cytopathy and chronic progressive external ophthalmoplegia. Binocul Vis Strabismus Q 2001; 16:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20726/abstract/25\">",
"      Andrews RM, Griffiths PG, Chinnery PF, Turnbull DM. Evaluation of bupivacaine-induced muscle regeneration in the treatment of ptosis in patients with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome. Eye (Lond) 1999; 13 ( Pt 6):769.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6271 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20726=[""].join("\n");
var outline_f20_15_20726=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Kearns-Sayre syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oculopharyngeal muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myotonic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Myotubular myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6271\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6271|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/16/20748\" title=\"table 1\">",
"      Causes of ophthalmoplegia children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/4/10317\" title=\"table 2\">",
"      Evaluation metabolic myopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=related_link\">",
"      Approach to the infant with hypotonia and weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26790?source=related_link\">",
"      Causes of vertical strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=related_link\">",
"      Congenital myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=related_link\">",
"      Oculopharyngeal, distal, and congenital muscular dystrophies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=related_link\">",
"      Renal involvement in the mitochondrial cytopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=related_link\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_15_20727="Bone curettage samples ECD";
var content_f20_15_20727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Bone curettage samples in Erdheim-Chester disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone curettage samples (panels A and B) from a patient with Erdheim-Chester disease demonstrate tissue infiltration by sheets of foamy (xanthomatous) histiocytes with interspersed inflammatory cells and multinucleate giant cells (Touton cells). The histiocytes express the histiocyte markers CD68 (panel C) and CD163 (panel D), but do not express CD1a (panel E) or Langerin (panel F).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20727=[""].join("\n");
var outline_f20_15_20727=null;
var title_f20_15_20728="Thoracoabdominal abdominal aortic aneurysm 3D reconstruction";
var content_f20_15_20728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Thoracoabdominal abdominal aortic aneurysm 3D reconstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 477px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A thoracoabdominal aortic aneurysm (arrow) involving the distal descending thoracic aorta and proximal abdominal aorta is shown in the reconstructed CT image. The diameters of the proximal thoracic aorta and distal abdominal aorta are normal.",
"    <div class=\"footnotes\">",
"     CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20728=[""].join("\n");
var outline_f20_15_20728=null;
var title_f20_15_20729="Pathology and pathogenesis of the vulnerable plaque";
var content_f20_15_20729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathology and pathogenesis of the vulnerable plaque",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/15/20729/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20729/contributors\">",
"     Fumiyuki Otsuka, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20729/contributors\">",
"     Masataka Nakano, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20729/contributors\">",
"     Frank Kolodgie, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20729/contributors\">",
"     Renu Virmani, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/15/20729/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20729/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20729/contributors\">",
"     Peter Libby, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/15/20729/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/15/20729/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/15/20729/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13450275\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute coronary syndromes represent a clinical spectrum of acute coronary artery disease that includes unstable angina, acute myocardial infarction, and sudden coronary arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\", section on 'Myocardial ischemia and infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most acute coronary syndromes are believed to result from the loss of integrity of a protective covering over an atherosclerotic plaque; this occurs with plaque rupture or erosion. This disruption of the protective covering allows blood to come in contact with the highly thrombogenic contents of the necrotic",
"    <span class=\"nowrap\">",
"     core/collagen",
"    </span>",
"    of the plaque and luminal thrombosis to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Intraluminal thrombosis after exposure of the blood to calcified nodules has also been observed. ACS can also result from other mechanisms such as a supply-demand mismatch.",
"   </p>",
"   <p>",
"    Autopsy studies has shown that when intraluminal thrombi are identified in patients with sudden cardiac death and acute myocardial infarction, the underlying pathology is rupture 55 to 75 percent of the time, erosion 25 to 40 percent of the time, and 2 to 7 percent for calcified nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/1,3-10\">",
"     1,3-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic focuses on the process of plaque progression and the development of the vulnerable plaque. The contribution of plaque rupture to the development of acute coronary syndromes, including the mechanisms of coronary thrombosis, and potential strategies to detect and treat rupture-prone vulnerable plaques, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450283\">",
"    <span class=\"h1\">",
"     PATHOLOGY OF CORONARY ATHEROSCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerosis is a dynamic process with multiple stages: intimal thickening, fibrous cap atheroma (fibroatheroma) formation, thin-cap fibroatheroma formation, and plaque rupture (",
"    <a class=\"graphic graphic_figure graphicRef71847 \" href=\"UTD.htm?14/44/15050\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80581 \" href=\"UTD.htm?23/15/23799\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/1\">",
"     1",
"    </a>",
"    ]. To understand plaque rupture, it is useful to review the stages of development of a plaque.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450294\">",
"    <span class=\"h2\">",
"     Intimal thickening and intimal xanthoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pre-existing lesions of adaptive intimal thickening (flow related intimal thickening is observed at branch points soon after birth) and intimal xanthoma (&ldquo;fatty streaks&rdquo;) are the earliest manifestations of atherosclerotic disease. While some plaques may begin as fatty-streaks, considerable evidence suggests that the intimal thickening is the likely precursor to symptomatic atherosclerotic disease since these lesions occur in children at similar locations as advanced plaques in adults, while fatty streaks are known to regress [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/11\">",
"     11",
"    </a>",
"    ]. Histologically, intimal thickening consists mainly of smooth muscle cells and proteoglycan-collagen matrix with little or no infiltrating inflammatory cells. Fatty streaks are predominantly observed at branch points correspond to the accumulation of macrophages within the intima and regress with age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450301\">",
"    <span class=\"h2\">",
"     Pathologic intimal thickening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stage between intimal",
"    <span class=\"nowrap\">",
"     thickening/initial",
"    </span>",
"    xanthoma and more advanced fibroatheromas is called pathologic intimal thickening, and is characterized by extracellular lipid pools containing proteoglycans in the absence of necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. The lipid pools tend to develop within areas of adaptive intimal thickening and are generally located in the deeper intimal layers near the arterial media. When present, macrophage and T lymphocytic infiltrates are near the luminal surface restricted from area of accumulated lipid. Early calcification may be seen and likely results from the death of smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/14\">",
"     14",
"    </a>",
"    ]. Pathologic intimal thickening can be a prelude to plaque erosion and the development of complications attributed to luminal thrombi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450309\">",
"    <span class=\"h2\">",
"     Fibrous cap atheroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first of the advanced coronary lesions is the fibrous cap atheroma (fibroatheroma) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. This lesion is characterized by a lipid-rich necrotic core encapsulated by fibrous tissue. The earliest phase is characterized by necrosis with macrophage infiltration in the area of a lipid pool, together with the focal loss of proteoglycans or collagen; the accumulation of free cholesterol is not readily apparent. In late fibroatheromas, discrete collections of cellular debris, increased free cholesterol, and near complete depletion of extracellular matrix is seen. The fibrous cap atheroma may develop into a lesion with a significant luminal stenosis after episodes of hemorrhage with or without calcification and surface disruption.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450322\">",
"    <span class=\"h2\">",
"     Thin-cap fibroatheroma (vulnerable plaque)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thin",
"    <strong>",
"     -",
"    </strong>",
"    cap fibroatheroma, also referred to as a vulnerable plaque, is identified by a large necrotic core (representing approximately 25 percent of plaque area) separated from the lumen by a thin fibrous cap, less than 65 &micro;min thickness. The fibrous cap is heavily infiltrated by macrophages and to a lesser extent T-lymphocytes (",
"    <a class=\"graphic graphic_picture graphicRef52661 \" href=\"UTD.htm?31/53/32600\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/6\">",
"     6",
"    </a>",
"    ]. Typically, the fibrous cap exhibits a paucity or absence of smooth muscle cells. This well characterized lesion is considered a prelude to rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/1,16\">",
"     1,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite morphologic similarities to lesions which have ruptured (see",
"    <a class=\"local\" href=\"#H13450329\">",
"     'Plaque rupture'",
"    </a>",
"    below) thin-cap fibroatheromas exhibit a trend towards smaller necrotic cores, fewer cap macrophages, and less calcification as compared to rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/17\">",
"     17",
"    </a>",
"    ]. Cross sectional luminal narrowing in thin-cap fibroatheromas is typically less as compared to underlying stenosis in acute ruptures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/17\">",
"     17",
"    </a>",
"    ]. The vast majority of thin-cap fibroatheromas (over 80 percent) in sudden coronary death victims have &lt;75 percent cross-sectional luminal-narrowing (or &lt;50 percent diameter stenosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174918727\">",
"    <span class=\"h3\">",
"     Reconsideration of the definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fibrous cap thickness of &lt;65 &micro;m is a widely accepted definition of thin-fibrous cap. This definition is based on the postmortem studies of plaque ruptures, which showed that the thickness of the fibrous cap near the rupture site was 23 &plusmn; 19 &micro;m, with 95 percent of the cap measuring less than 64 &micro;m [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/6\">",
"     6",
"    </a>",
"    ]. However, given that tissue fixation and processing result in an approximately 40 percent decrease in arterial wall area in human coronary arteries with moderate to severe atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/19\">",
"     19",
"    </a>",
"    ], it may not be an appropriate cut-off value for the evaluation of rupture-prone plaques in vivo. In fact, optical coherence tomography (OCT) studies evaluating patients with plaque ruptures have demonstrated that the disrupted fibrous cap thickness &lt;70 &micro;m was observed only in 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/20\">",
"     20",
"    </a>",
"    ], and median (interquartile range) value of cap thickness was 54 (50 to 60) &micro;m, with 95 percent of the thinnest cap thickness measuring less than 80 &micro;m [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=see_link\">",
"     \"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=see_link&amp;anchor=H321552326#H321552326\">",
"     \"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation\", section on 'Optical coherence tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the existence of thin-cap fibroatheromas does not necessarily imply that plaque rupture is imminent, further prospective studies together with these OCT findings should address the appropriate definition of thin-fibrous cap thickness in vivo. Importantly, it is essential to define the critical surrogates of lesion instability to help identify patients at the highest risk of rupture and future coronary events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450329\">",
"    <span class=\"h2\">",
"     Plaque rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morphologically, a plaque which has ruptured shows an intraluminal thrombus overlying a thin disrupted fibrous cap, which is infiltrated by macrophages and T-lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/22\">",
"     22",
"    </a>",
"    ]. The thrombus is in contact with an underlying necrotic core (",
"    <a class=\"graphic graphic_picture graphicRef61067 \" href=\"UTD.htm?36/40/37514\">",
"     picture 2",
"    </a>",
"    ). The fibrous cap consists mainly of type I collagen with varying degrees of macrophages and lymphocytes, whereas the smooth muscle cells component within the cap is absent or sparse. In lesions which have ruptured, the mean thickness of the fibrous cap is 23 &plusmn; 19 &mu;m, with 95 percent of the cap measuring less than 64 &mu;m [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/6\">",
"     6",
"    </a>",
"    ]. Although it has been widely accepted that fibrous cap rupture occurs at its weakest point often near shoulder regions, autopsy studies using serially cut sections demonstrate an equal number of ruptures occurring at the midportion of the fibrous cap [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disruption of part of the fibrous cap allows circulating cellular and noncellular elements of the blood to come in direct contact with the highly thrombogenic components of the necrotic core, including tissue factor. Historically, the necrotic core was thought to be the principle source of the tissue factor, an important stimulus for platelet activation. However, it is now believed that circulating monocytes, instead of macrophages within the lesions, can also furnish tissue factor that can trigger and propagate thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/23\">",
"     23",
"    </a>",
"    ]. Leukocytes and platelets interact via CD15 (a leukocyte membrane-bound carbohydrate known as sialyl Lewis",
"    <sup>",
"     x",
"    </sup>",
"    ) with P-selectin, which is an &alpha; granule-derived activation-dependent adhesion molecule found on platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/24\">",
"     24",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    At the rupture site, the luminal thrombus often is platelet-rich thereby giving rise to a grossly white appearance (white thrombus), while at the proximal and distal ends near the sites of propagation of the thrombosis it appears red (red thrombus) as it is composed of layers of fibrin and red blood cells.",
"    <strong>",
"    </strong>",
"    Over time, thrombus healing is characterized by an infiltration of smooth muscle cells, accumulated extracellular matrix proteins (ie, proteoglycans and collagen), neovascularization, inflammation, and luminal surface reendothelialization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450341\">",
"    <span class=\"h2\">",
"     Plaque erosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaque erosion represents the second most common lesion associated with acute thrombosis in the coronary circulation. Erosions differ from rupture lesions, as there is an absence of fibrous cap disruption. The primary characteristics of plaque erosion include an abundance of smooth muscle cells and proteoglycan matrix and absence of surface endothelium without a prominent lipid core [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/25\">",
"     25",
"    </a>",
"    ]. There is no communication between necrotic core and the lumen. There is either absent or few macrophages and T-lymphocytes close to the lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The underlying lesion morphology also differs from rupture since it involves early lesions, that is pathologic intimal thickening or to a lesser extent, fibroatheromas without an extensive necrotic core, hemorrhage, or calcification. There is no communication between necrotic core and the lumen. There is either no or few macrophages and T-lymphocytes close to the lumen. The luminal surface of erosion is separated from flowing blood by a platelet rich thrombus adhered to the proteoglycan rich intima. The absence of endothelium, secondary to apoptotic loss of endothelial cells, allows flowing blood to come in contact with collagen and induced thrombus formation.",
"   </p>",
"   <p>",
"    It is not well understood why some lesions rupture and others erode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450348\">",
"    <span class=\"h2\">",
"     Calcified nodule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcified nodule is the lesion least frequently associated with luminal thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/1\">",
"     1",
"    </a>",
"    ]. This term is reserved for fibrocalcific plaques with eruptive, dense, calcific nodules that disrupt the luminal surface. Little or no underlying necrotic core is seen. Heavily calcified arteries often show large plates of calcified matrix with surrounding areas of fibrosis, inflammation, and neovascularization. Although the precise nature of this lesion remains incompletely understood, fragmentation of the calcified plates is believed to represent the etiology of the nodular calcification where even sometimes bone formation can be observed with interspersed fibrin. These lesions are generally more prevalent in older males with tortuous coronary and heavily calcified arteries. The calcified nodule erodes into the lumen allowing the calcium to directly contact flowing blood and stimulate thrombus formation.",
"   </p>",
"   <p>",
"    Additional clinical correlates of calcified nodules in patients with prior acute coronary syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link&amp;anchor=H13452804#H13452804\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\", section on 'Calcified nodule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450356\">",
"    <span class=\"h2\">",
"     Healed rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healed lesions occur at sites of prior rupture with thrombus formation, which may or may not be associated with symptoms. They are defined as a third category of atherosclerotic plaques, the other two being non-progressive and progression prone plaques.",
"   </p>",
"   <p>",
"    Ruptured lesions with healed repair sites are designated as the healed plaque ruptures. They are identified on the basis of a disrupted fibrous cap with an overlying repair reaction consisting of smooth muscle cells surrounded by proteoglycans",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a collagen rich matrix depending on the phase of healing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/26\">",
"     26",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    The matrix within the healed fibrous cap generally begins as an early proteoglycan-rich mass along with type III collagen, which eventually progresses into a type I collagen-rich lesion from healing of the thrombus (",
"    <a class=\"graphic graphic_picture graphicRef63329 \" href=\"UTD.htm?25/10/25769\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healed ruptures frequently exhibit multiple layers of necrotic cores interspersed by fibrous tissue (so-called buried caps) with the earliest of rupture sites located in deeper intima suggestive of previous thrombotic events, which sequentially lead to lesion progression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/27\">",
"     27",
"    </a>",
"    ]. Primarily based on autopsy findings from sudden coronary deaths, healed ruptures contribute to a significant increase in plaque burden and luminal narrowing. They generally occur in the absence of cardiac symptoms. First time ruptures that precipitate sudden cardiac death are responsible for only 11 percent of acute thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In plaques with less than 20 percent diameter stenosis, the incidence of healed plaque rupture is 16 percent; in lesions with 21 to 50 percent stenosis the incidence is 19 percent; and in plaques with greater than 50 percent narrowing, the incidence is 73 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450371\">",
"    <span class=\"h1\">",
"     MECHANISMS OF PLAQUE PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The section above describes the pathologic changes that occur in the arterial wall at the site of plaque formation. This section will discuss some of the underlying pathophysiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450379\">",
"    <span class=\"h2\">",
"     Inflammation and plaque progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerosis is an inflammatory disease, with monocyte infiltration being one of the early steps [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/28\">",
"     28",
"    </a>",
"    ]. The presence of intimal lipoproteins and their derived or modified products causes an increase in the expression of adhesion molecules on the endothelial surface. Adhesion of inflammatory cells involves the expression of selectins, which facilitate the firm attachment of monocytes to endothelial integrins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is believed that oxidation of the low-density lipoprotein (LDL) is a requirement for the initiation and progression of atherosclerosis and is promoted by macrophages, endothelial cells, and smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. LDL oxidation has been shown to occur as a result of lipoxygenases, hypochlorous acid produced by myeloperoxidase, nitric oxide produced by inducible nitric oxide synthase, and superoxide anion produced by NADPH oxidase [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Such reactive oxygen species derive from macrophages, endothelial cells, and SMCs. Oxidized LDL promotes chemoattraction, for example, by inducing the secretion of macrophage-chemotactic protein-1 (MCP-1) by endothelial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Moreover, macrophages express several scavenger receptors, which can bind a broad spectrum of ligands, including modified lipoproteins, native lipoproteins, and anionic phospholipids, many of which facilitate the massive accumulation of intracellular cholesterol esters and free cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macrophages and endothelial cells also express Toll-like receptors (TLRs) on their cell surface, and contain various adaptor molecules (in particular MyD88) that participate in transmembrane signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/35\">",
"     35",
"    </a>",
"    ]. TLRs activate the proinflammatory transcription factor nuclear factor kappa-B (NF-&kappa;B), resulting in the production of cytokines that augment local inflammation and smooth muscle cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In vitro studies have shown that basal expression of TLR-4 by macrophages is upregulated by oxidized LDL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/38\">",
"     38",
"    </a>",
"    ], thereby providing a potential pathophysiological link between lipid accumulation, inflammatory cytokines, and atherosclerosis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450386\">",
"    <span class=\"h2\">",
"     Formation and expansion of the necrotic core",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotic core formation is caused by death of lipid-laden macrophages, also referred to as foam cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Foam cells contain cholesterol esters and free cholesterol. As plaques progress, the free cholesterol content of the lesion increases, as does the free-to-esterified cholesterol ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Macrophages initially accumulate mostly cholesterol esters, but macrophages in advanced lesions contain large amounts of free cholesterol. A high ratio of free cholesterol to phospholipid in cellular membrane has been shown to be toxic to cells and therefore free cholesterol induced cytotoxity may contribute to foam cell necrosis, leading to the expansion of the necrotic core (",
"    <a class=\"graphic graphic_figure graphicRef79961 \" href=\"UTD.htm?21/9/21658\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13450309\">",
"     'Fibrous cap atheroma'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450393\">",
"    <span class=\"h2\">",
"     Apoptosis and necrotic core expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the accumulation of lipid-laden foamy macrophages has an important impact on atherosclerotic lesion growth, these macrophages eventually die mainly through mechanisms involving apoptosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=see_link&amp;anchor=H1#H1\">",
"     \"Apoptosis and autoimmune disease\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although macrophage apoptosis occurs throughout all stages of atherosclerosis, apoptotic macrophages are more frequently observed in advanced atherosclerotic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/44\">",
"     44",
"    </a>",
"    ]. Extensive in vivo investigations suggest that the efficiency of phagocytic clearance of apoptotic cells may be supportive in early lesions with minimal effect on lesion cellularity, whereas for late lesions, macrophages may exhibit a defective phagocytic clearance, where remnants of dead cells can lead to activation of proinflammatory responses and subsequent necrotic core expansion and lesion progression (",
"    <a class=\"graphic graphic_figure graphicRef79961 \" href=\"UTD.htm?21/9/21658\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Murine studies have identified important effector molecules on macrophages such as tyrosine-kinase defective Mertk receptors or transglutaminase-2 (TG2) that may play a role in the defective clearance of apoptotic cells in atherosclerotic plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450408\">",
"    <span class=\"h2\">",
"     Intraplaque hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraplaque hemorrhage is another important contributing factor to the enlargement of necrotic core. Although apoptotic macrophages may be a source of free cholesterol in the development and expansion of the necrotic core, it is unlikely that the total free cholesterol in plaques derive from foam cells alone, since a large part of the cholesterol in foam cells is esterified. Some of the cholesterol crystals in lesions are derived from red cells as they are frequently observed at sites of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/49\">",
"     49",
"    </a>",
"    ]. Also, the cholesterol content of erythrocyte membrane is the richest in free cholesterol of all cells in the body. Hemorrhage into the necrotic core is a common event and therefore it is likely that the free cholesterol in the necrotic cores also comes from red cell membranes (",
"    <a class=\"graphic graphic_figure graphicRef79961 \" href=\"UTD.htm?21/9/21658\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef58344 \" href=\"UTD.htm?6/36/6728\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The source of hemorrhage is probably mainly from leaky vasa vasorum that infiltrate the plaque from the adventitia in response to a hypoxic environment created by increased lesion burden and inflammatory macrophages. The vasa vasorum within plaques typically lack an intact basement membrane, are poorly stabilized by surrounding pericytes, and exhibit poor endothelial junctions, which is likely responsible for their acquired lack of integrity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168035608\">",
"    <span class=\"h2\">",
"     Coronary arterial remodeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in lesion burden compromises lumen size only when 40 percent or greater cross-sectional luminal narrowing is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/51\">",
"     51",
"    </a>",
"    ]. The absence of luminal loss independent of lesion burden in early plaques has been linked to compensatory enlargement of the vessel, ie, positive coronary arterial remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postmortem and intravascular ultrasound studies have revealed that positive remodeling of the coronary arterial wall is associated with a higher lipid content and macrophage infiltration as well as unstable plaque features such as acute rupture, intraplaque hemorrhage, and thin-cap fibroatheromas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Conversely, lesions of erosion or chronic total occlusion exhibit negative remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/53\">",
"     53",
"    </a>",
"    ]. Thus, arterial remodeling may represent one important surrogate for the detection of lesion vulnerability and thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450422\">",
"    <span class=\"h1\">",
"     MECHANISMS OF PLAQUE RUPTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the precise mechanism(s) of plaque rupture are poorly understood, it is widely accepted that disruption occurs at the site of the fibrous cap, which is heavily infiltrated by macrophages and T-lymphocytes where the underlying necrotic core is typically large [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/1,28\">",
"     1,28",
"    </a>",
"    ]. While necrotic core expansion and positive remodeling may be associated with plaque progression and lesion vulnerability, the actual degradation of fibrous cap is thought to occur through the breakdown of extracellular matrix proteins by secreted matrix metalloproteinases (MMPs). This, together with other critical factors such as apoptosis and local rheological forces including vasospasm, has been implicated in the development of plaque rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450437\">",
"    <span class=\"h2\">",
"     Collagen synthesis and breakdown in the fibrous cap",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular smooth muscle cells synthesize essential extracellular matrix proteins such as collagen and elastin from amino acids. Fibrillar collagens, especially type I collagen, provide most of the tensile strength to the fibrous cap. The process of collagen synthesis may be inhibited by interferon gamma (INF-&gamma;) secreted by activated T-cells (",
"    <a class=\"graphic graphic_figure graphicRef65967 \" href=\"UTD.htm?42/41/43671\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/55\">",
"     55",
"    </a>",
"    ]. Moreover, T-cell activation leads to the expression of CD40 ligands",
"    <span class=\"nowrap\">",
"     (CD40L/CD154),",
"    </span>",
"    which binds to CD40 receptors on the macrophages, B-lymphocytes, and other cells including endothelial and smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/28,56-58\">",
"     28,56-58",
"    </a>",
"    ]. The expression of CD40L on T-cells promotes tissue proteolysis through the release of MMPs.",
"   </p>",
"   <p>",
"    The loss of fibrillar collagen by activated MMPs is thought to be responsible for fibrous cap thinning and therefore may play a pivotal role in the development of plaque rupture (",
"    <a class=\"graphic graphic_figure graphicRef65967 \" href=\"UTD.htm?42/41/43671\">",
"     figure 4",
"    </a>",
"    ). The initial proteolytic nick in the collagen chain is provided by collagenases MMPs-1, -8, and -13 while the gelatinases MMP-2 and -9 support further breakdown of collagen fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/28,59-62\">",
"     28,59-62",
"    </a>",
"    ]. On the other hand, the artery also possesses endogenous antagonists to MMPs, the tissue inhibitors of metalloproteinases (TIMPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/29\">",
"     29",
"    </a>",
"    ]. Atheromatous plaques exhibit cleavage of type I collagen at the sites that are rich in macrophages expressing both MMP-1 and -13 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/62\">",
"     62",
"    </a>",
"    ]. Other proteinases capable of degrading extracellular matrix include the cathepsin family (cathepsins S and K) and the inhibitor cystatin C [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/63\">",
"     63",
"    </a>",
"    ]. Unlike collagen breakdown by MMPs, elastolytic activity however, has been implicated more with matrix remodeling and migration and proliferation of cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/60\">",
"     60",
"    </a>",
"    ]. While elastolysis may be more important in aneurysm formation, collagenolysis may be a major determinant of plaque rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450444\">",
"    <span class=\"h2\">",
"     Apoptosis and plaque rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apoptosis may also play a critical role in the development of plaque rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/65\">",
"     65",
"    </a>",
"    ]. Macrophage and smooth muscle cell apoptosis have been observed in both progression and regression of the atherosclerotic plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/66\">",
"     66",
"    </a>",
"    ]. Plaque rupture sites typically show fewer or an absence of smooth muscle cells, which are the principal cells required for the synthesis of extracellular matrix proteins and maintenance of the fibrous cap. In vitro studies have shown that various mediators secreted by macrophages and T-lymphocytes including IFN-&gamma;, Fas ligand, tumor necrosis factor-&alpha; (TNF-&alpha;), interleukin-1 (IL-1), and reactive oxygen species (ROS), can promote smooth muscle cell apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/67\">",
"     67",
"    </a>",
"    ], which may account for the decrease in smooth muscle cells seen in thin cap fibroatheroma and ruptured plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although macrophage apoptosis is frequently observed at the sites of plaque rupture, it remains unknown whether apoptosis alone is capable of triggering the primary event [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/69\">",
"     69",
"    </a>",
"    ]. In vitro studies have identified potent mediators, such as oxidized LDL, as capable of inducing macrophage apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/65\">",
"     65",
"    </a>",
"    ]. INF-&gamma; has been shown to induce apoptotic cell death of THP-1 macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/66\">",
"     66",
"    </a>",
"    ], while it also leads to further synthesis of macrophage chemoattractant protein-1 (MCP-1), which may promote additional inflammatory responses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450451\">",
"    <span class=\"h2\">",
"     Local mechanical stress and plaque rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although tissue proteolysis and apoptosis within the fibrous cap are believed to be important in the development of plaque rupture, the event may also reflect an effect of local factors related to blood flow dynamics and vasospasm.",
"   </p>",
"   <p>",
"    A number of biomechanical and imaging studies have emerged since the 1990s addressing the role of hemodynamic shear stress in the destabilization of vulnerable plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. The underlying premise is based on the observation that atherosclerosis develops focally, where rupture occurs more frequently proximal to regions of severe stenosis near flow dividers, an area where circumferential wall stress is assumed to be the highest. Consistent with these observations, blood flow-induced shear stress may also represent a significant influence on processes that govern fibrous cap morphology and composition [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/73\">",
"     73",
"    </a>",
"    ], where increased peak circumferential stress is greater in thinner fibrous caps [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/70\">",
"     70",
"    </a>",
"    ]. Therefore, regions high shear stress typically exhibit high strain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/72\">",
"     72",
"    </a>",
"    ], thus supporting the notion that mechanical stress when applied to the weakened fibrous cap may precipitate rupture, particularly in the presence of microcalcification [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H237640\">",
"    <span class=\"h1\">",
"     MECHANISMS OF EROSION AND PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for erosion are poorly understood and are different from those for rupture. Consistently, plaque erosion is associated with smoking and is predominantly seen in premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/7,22\">",
"     7,22",
"    </a>",
"    ]. It has been speculated that coronary vasospasm might be involved in the pathophysiology of erosion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     plaque/thrombus",
"    </span>",
"    interface in erosion is unique, consisting of proteoglycans (specifically versican) and hyaluronan; there are often aberrant smooth muscle cells with few or no inflammatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. The lack of a significant inflammatory response raises the possibility that erosions represent chronic wounding and tissue repair rather than a direct atherogenic process.",
"   </p>",
"   <p>",
"    Postmortem studies have shown that coronary thrombi superimposed on eroded plaques contain a higher density of myeloperoxidase-positive cells than thrombi superimposed on ruptured plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/76\">",
"     76",
"    </a>",
"    ]. Systemic myeloperoxidase levels are also elevated in patients with acute coronary syndromes presenting with eroded plaques as compared to those presenting with rupture, suggesting that elevations in selective inflammatory biomarkers may reflect specific acute coronary events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/76\">",
"     76",
"    </a>",
"    ]. It is hypothesized that a selective accumulation of hyaluronan and proteoglycans in eroded plaques my promote the endothelialization and platelet thrombus formation along with accumulation of circulating neutrophils and monocyte-expressing myeloperoxidase, which may further lead to endothelial cell death and thus promote thrombus formation. Because erosive thrombi in sudden coronary thrombotic death show 85 percent as organizing lesions versus only 50 percent in plaque rupture we believe that organization of the thrombus plays an important role in progression of the plaque area [",
"    <a class=\"abstract\" href=\"UTD.htm?20/15/20729/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13450465\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most acute coronary syndromes (ACS) result from the loss of integrity of the protective covering over an atherosclerotic plaque. This occurs with plaque rupture, plaque erosion, or calcified nodule. The loss of the protective endothelial covering allows blood to come in contact with the highly thrombogenic contents of collagen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      necrotic core of the plaque and luminal thrombosis to occur.",
"      <br/>",
"      Other mechanisms can cause ACS, including a supply-demand mismatch.",
"     </li>",
"     <li>",
"      The precursor lesion of plaque rupture has been designated as thin-cap fibroatheroma, which is a descriptive term that was traditionally called a vulnerable plaque. In a more conservative sense, however, the term &ldquo;vulnerable&rdquo; should be used for lesions that underlie all causes of coronary thrombi.",
"     </li>",
"     <li>",
"      Plaque rupture is the major cause of acute coronary thrombi (70 percent). It is characterized by lesions that exhibit relatively large necrotic cores with a thin disrupted fibrous cap. Luminal blood comes in direct communication with the necrotic core and thrombosis may result.",
"     </li>",
"     <li>",
"      While the precise pathogenetic mechanism of plaque rupture is unclear, factors such as the destruction of extracellular matrix within the fibrous cap by metalloproteinases as well as macrophage apoptosis and the influence of local rheological forces are likely involved.",
"     </li>",
"     <li>",
"      Ruptured plaques are associated with positive remodeling. Thus, a high percentage of acute coronary syndromes are attributed to plaque rupture and occur in lesions with &lt;50 percent diameter stenosis. Repeated ruptures, which may or may not be silent, are likely responsible for plaque progression and the formation of obstructive lesions.",
"     </li>",
"     <li>",
"      Pathogenetic mechanisms of plaque erosion are poorly understood, however, the presence of hyaluronan in the superficial layers close to the thrombus suggests their role in deendothelialization and platelet adherence.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/1\">",
"      Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/2\">",
"      Burke AP, Farb A, Malcom GT, et al. Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA 1999; 281:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/3\">",
"      Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/4\">",
"      el Fawal MA, Berg GA, Wheatley DJ, Harland WA. Sudden coronary death in Glasgow: nature and frequency of acute coronary lesions. Br Heart J 1987; 57:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/5\">",
"      Davies MJ, Bland JM, Hangartner JR, et al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/6\">",
"      Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/7\">",
"      Burke AP, Farb A, Malcom GT, et al. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998; 97:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/8\">",
"      Arbustini E, Dal Bello B, Morbini P, et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 1999; 82:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/9\">",
"      Kubo T, Imanishi T, Takarada S, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol 2007; 50:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/10\">",
"      Ino Y, Kubo T, Tanaka A, et al. Difference of culprit lesion morphologies between ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. JACC Cardiovasc Interv 2011; 4:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/11\">",
"      Velican C. A dissecting view on the role of the fatty streak in the pathogenesis of human atherosclerosis: culprit or bystander? Med Interne 1981; 19:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/12\">",
"      McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 2000; 20:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/13\">",
"      Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/14\">",
"      Kolodgie FD, Burke AP, Nakazawa G, Virmani R. Is pathologic intimal thickening the key to understanding early plaque progression in human atherosclerotic disease? Arterioscler Thromb Vasc Biol 2007; 27:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/15\">",
"      Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/16\">",
"      Davies MJ, Thomas AC. Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/17\">",
"      Kolodgie FD, Burke AP, Farb A, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol 2001; 16:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/18\">",
"      Kolodgie FD, Virmani R, Burke AP, et al. Pathologic assessment of the vulnerable human coronary plaque. Heart 2004; 90:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/19\">",
"      Siegel RJ, Swan K, Edwalds G, Fishbein MC. Limitations of postmortem assessment of human coronary artery size and luminal narrowing: differential effects of tissue fixation and processing on vessels with different degrees of atherosclerosis. J Am Coll Cardiol 1985; 5:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/20\">",
"      Tanaka A, Imanishi T, Kitabata H, et al. Morphology of exertion-triggered plaque rupture in patients with acute coronary syndrome: an optical coherence tomography study. Circulation 2008; 118:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/21\">",
"      Yonetsu T, Kakuta T, Lee T, et al. In vivo critical fibrous cap thickness for rupture-prone coronary plaques assessed by optical coherence tomography. Eur Heart J 2011; 32:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/22\">",
"      Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/23\">",
"      Nemerson Y. A simple experiment and a weakening paradigm: the contribution of blood to propensity for thrombus formation. Arterioscler Thromb Vasc Biol 2002; 22:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/24\">",
"      Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/25\">",
"      Kolodgie FD, Burke AP, Farb A, et al. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler Thromb Vasc Biol 2002; 22:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/26\">",
"      Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999; 82:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/27\">",
"      Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/28\">",
"      Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/29\">",
"      Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/30\">",
"      Babior BM. Phagocytes and oxidative stress. Am J Med 2000; 109:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/31\">",
"      Endemann G, Stanton LW, Madden KS, et al. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 1993; 268:11811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/32\">",
"      Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002; 8:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/33\">",
"      Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002; 8:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/34\">",
"      Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001; 11:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/35\">",
"      Pearson AM. Scavenger receptors in innate immunity. Curr Opin Immunol 1996; 8:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/36\">",
"      Muzio M, Mantovani A. Toll-like receptors (TLRs) signalling and expression pattern. J Endotoxin Res 2001; 7:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/37\">",
"      Faure E, Thomas L, Xu H, et al. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 2001; 166:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/38\">",
"      Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104:3103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/39\">",
"      Kruth HS. Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin-positive, oil-red-O-negative particles. Am J Pathol 1984; 114:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/40\">",
"      Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996; 16:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/41\">",
"      Katz SS, Shipley GG, Small DM. Physical chemistry of the lipids of human atherosclerotic lesions. Demonstration of a lesion intermediate between fatty streaks and advanced plaques. J Clin Invest 1976; 58:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/42\">",
"      Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997; 17:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/43\">",
"      Tabas I. Free cholesterol-induced cytotoxicity a possible contributing factor to macrophage foam cell necrosis in advanced atherosclerotic lesions. Trends Cardiovasc Med 1997; 7:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/44\">",
"      Kockx MM. Apoptosis in the atherosclerotic plaque: quantitative and qualitative aspects. Arterioscler Thromb Vasc Biol 1998; 18:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/45\">",
"      Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005; 25:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/46\">",
"      Schrijvers DM, De Meyer GR, Kockx MM, et al. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/47\">",
"      Thorp E, Cui D, Schrijvers DM, et al. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/- mice. Arterioscler Thromb Vasc Biol 2008; 28:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/48\">",
"      Boisvert WA, Rose DM, Boullier A, et al. Leukocyte transglutaminase 2 expression limits atherosclerotic lesion size. Arterioscler Thromb Vasc Biol 2006; 26:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/49\">",
"      Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/50\">",
"      Sluimer JC, Kolodgie FD, Bijnens AP, et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol 2009; 53:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/51\">",
"      Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/52\">",
"      Clarkson TB, Prichard RW, Morgan TM, et al. Remodeling of coronary arteries in human and nonhuman primates. JAMA 1994; 271:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/53\">",
"      Burke AP, Kolodgie FD, Farb A, et al. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 2002; 105:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/54\">",
"      Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002; 105:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/55\">",
"      Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91:2844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/56\">",
"      Lutgens E, van Suylen RJ, Faber BC, et al. Atherosclerotic plaque rupture: local or systemic process? Arterioscler Thromb Vasc Biol 2003; 23:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/57\">",
"      Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/58\">",
"      Hansson GK, Libby P, Sch&ouml;nbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/59\">",
"      Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am J Cardiol 2000; 86:3J.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/60\">",
"      Dollery CM, Owen CA, Sukhova GK, et al. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation 2003; 107:2829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/61\">",
"      Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001; 104:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/62\">",
"      Sukhova GK, Sch&ouml;nbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/63\">",
"      Sukhova GK, Shi GP, Simon DI, et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/64\">",
"      Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/65\">",
"      Kolodgie FD, Narula J, Guillo P, Virmani R. Apoptosis in human atherosclerotic plaques. Apoptosis 1999; 4:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/66\">",
"      Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 2002; 22:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/67\">",
"      Geng YJ, Henderson LE, Levesque EB, et al. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/68\">",
"      Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995; 95:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/69\">",
"      Kolodgie FD, Narula J, Burke AP, et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol 2000; 157:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/70\">",
"      Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992; 71:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/71\">",
"      Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999; 282:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/72\">",
"      Gijsen FJ, Wentzel JJ, Thury A, et al. Strain distribution over plaques in human coronary arteries relates to shear stress. Am J Physiol Heart Circ Physiol 2008; 295:H1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/73\">",
"      Slager CJ, Wentzel JJ, Gijsen FJ, et al. The role of shear stress in the generation of rupture-prone vulnerable plaques. Nat Clin Pract Cardiovasc Med 2005; 2:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/74\">",
"      Vengrenyuk Y, Carlier S, Xanthos S, et al. A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl Acad Sci U S A 2006; 103:14678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/75\">",
"      Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47:C13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/76\">",
"      Ferrante G, Nakano M, Prati F, et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation 2010; 122:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/15/20729/abstract/77\">",
"      Kramer MC, Rittersma SZ, de Winter RJ, et al. Relationship of thrombus healing to underlying plaque morphology in sudden coronary death. J Am Coll Cardiol 2010; 55:122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1539 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-E320E62127-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20729=[""].join("\n");
var outline_f20_15_20729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13450465\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13450275\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13450283\">",
"      PATHOLOGY OF CORONARY ATHEROSCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450294\">",
"      Intimal thickening and intimal xanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450301\">",
"      Pathologic intimal thickening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450309\">",
"      Fibrous cap atheroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450322\">",
"      Thin-cap fibroatheroma (vulnerable plaque)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174918727\">",
"      - Reconsideration of the definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450329\">",
"      Plaque rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450341\">",
"      Plaque erosion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450348\">",
"      Calcified nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450356\">",
"      Healed rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13450371\">",
"      MECHANISMS OF PLAQUE PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450379\">",
"      Inflammation and plaque progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450386\">",
"      Formation and expansion of the necrotic core",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450393\">",
"      Apoptosis and necrotic core expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450408\">",
"      Intraplaque hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168035608\">",
"      Coronary arterial remodeling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13450422\">",
"      MECHANISMS OF PLAQUE RUPTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450437\">",
"      Collagen synthesis and breakdown in the fibrous cap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450444\">",
"      Apoptosis and plaque rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13450451\">",
"      Local mechanical stress and plaque rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H237640\">",
"      MECHANISMS OF EROSION AND PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13450465\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1539\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1539|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/44/15050\" title=\"figure 1\">",
"      Progression of human coronary atherosclerosis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/15/23799\" title=\"figure 2\">",
"      Progression of human coronary atherosclerosis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/9/21658\" title=\"figure 3\">",
"      Mechanism of necrotic core expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/41/43671\" title=\"figure 4\">",
"      The role of collagen in the fibrous cap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1539|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/53/32600\" title=\"picture 1\">",
"      Thin-cap fibroatheroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/40/37514\" title=\"picture 2\">",
"      Gross and light microscopic features of plaque rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/10/25769\" title=\"picture 3\">",
"      Histologic images of healed plaque rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/36/6728\" title=\"picture 4\">",
"      Thin-cap fibroatheroma with intraplaque hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=related_link\">",
"      Apoptosis and autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=related_link\">",
"      Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_15_20730="Itraconazole: Drug information";
var content_f20_15_20730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Itraconazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/17/34069?source=see_link\">",
"    see \"Itraconazole: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/59/6074?source=see_link\">",
"    see \"Itraconazole: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Onmel&trade;;",
"     </li>",
"     <li>",
"      Sporanox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sporanox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F185468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F185425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;200 mg daily should be administered in 2 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Aspergillosis:",
"     </b>",
"     Oral: 200-400 mg daily.",
"     <b>",
"      Note:",
"     </b>",
"     For life-threatening infections, administer a loading dose of 200 mg 3 times daily (total: 600 mg daily) for the first 3 days of therapy. Continue treatment for at least 3 months and until clinical and laboratory evidence suggest that infection has resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Aspergillosis, invasive (salvage therapy):",
"     </b>",
"     Duration of therapy should be a minimum of 6-12 weeks or throughout period of immunosuppression: Oral: 200-400 mg daily;",
"     <b>",
"      Note:",
"     </b>",
"     2008 IDSA guidelines recommend 600 mg/day for 3 days, followed by 400 mg daily (Walsh, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Appropriate use:",
"     </i>",
"     Itraconazole should",
"     <b>",
"      NOT",
"     </b>",
"     be used for voriconazole-refractory aspergillosis since the same antifungal and/or resistance mechanism(s) may be shared by both agents. Itraconazole oral solution and capsule formulations are not bioequivalent or interchangeable. Due to variable bioavailability of oral preparations, therapeutic drug monitoring is advisable (Walsh, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Aspergillosis, allergic (ABPA, sinusitis):",
"     </b>",
"     Oral: 200 mg/day; may be used in conjunction with corticosteroids (Walsh, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Blastomycosis:",
"     </b>",
"     Oral: Initial: 200 mg once daily; if no clinical improvement or evidence of progressive infection, may increase dose in increments of 100 mg up to maximum of 400 mg daily.",
"     <b>",
"      Note:",
"     </b>",
"     For life-threatening infections, administer a loading dose of 200 mg 3 times daily (total: 600 mg daily) for the first 3 days of therapy. Continue treatment for at least 3 months and until clinical and laboratory evidence suggest that infection has resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Alternative dosing (Chapman, 2008):",
"     </i>",
"     200 mg 3 times daily for 3 days, then 200 mg twice daily for 6-12 months; in moderately-severe to severe infection, therapy should be initiated with ~2 weeks of  amphotericin B.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Candidiasis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Esophageal:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral solution: 100-200 mg once daily for a minimum of 3 weeks; continue dosing for 2 weeks after resolution of symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral capsules: Canadian labeling (not in U.S. labeling): 100 mg once daily for 4 weeks; increase dose to 200 mg once daily in patients with AIDS and neutropenic patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Oropharyngeal:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral solution: 200 mg once daily for 1-2 weeks; in patients unresponsive or refractory to fluconazole: 100 mg twice daily (clinical response expected in 2-4 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral capsules: Canadian labeling (not in U.S. labeling): 100 mg once daily for 2 weeks; increase dose to 200 mg once daily in patients with AIDS and neutropenic patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chromomycosis:",
"     </b>",
"     Canadian labeling (not in U.S. labeling): Oral: 200 mg once daily for 6 months (when due to",
"     <i>",
"      Fonsecaea pedrosoi",
"     </i>",
"     ) or 100 mg once daily for 3 months (when due to",
"     <i>",
"      Cladosporium carrioni",
"     </i>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Coccidioidomycosis (nonprogressive, nondisseminated disease):",
"     </b>",
"     200 mg twice daily or 3 times/day (Galgiani, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Histoplasmosis:",
"     </b>",
"     Oral: Manufacturer labeling: Initial: 200 mg once daily; if no clinical improvement or evidence of progressive infection, may increase dose in increments of 100 mg up to maximum of 400 mg daily.",
"     <b>",
"      Note:",
"     </b>",
"     For life-threatening infections, administer a loading dose of 200 mg 3 times daily (total: 600 mg daily) for the first 3 days of therapy. Continue treatment for at least 3 months and until clinical and laboratory evidence suggest that infection has resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Alternative dosing (Wheat, 2007):",
"     </i>",
"     200 mg 3 times daily for 3 days, then 200 mg twice daily (or once daily in mild-moderate disease) for 6-12 weeks in mild-moderate disease or &ge;12 months in progressive disseminated or chronic cavitary pulmonary histoplasmosis; in moderately-severe to severe infection, therapy should be initiated with ~2 weeks of a lipid formation of amphotericin B.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Long-term suppression therapy:",
"     </i>",
"     200 mg/day (CDC, 2009b)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Coccidioides:",
"     </i>",
"     400-600 mg/day (Galgiani, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Coccidioides, HIV-positive (unlabeled use):",
"     </i>",
"     200 mg 3 times/day for 3 days, then 200 mg twice daily; maintenance: 200 mg twice daily life-long (CDC, 2009b)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Appropriate use:",
"     </i>",
"     Fluconazole is preferred for meningeal infections (CDC,  2009b; Galgiani, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Onychomycosis:",
"     </b>",
"     Oral: 200 mg once daily for 12 consecutive weeks; alternative &ldquo;pulse-dosing&rdquo; may be considering for fingernail involvement only: 200 mg twice daily for 1 week; repeat 1-week course after 3-week off-time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Onychomycosis (toenails with or without fingernail involvement):",
"     </b>",
"     Canadian labeling (not in U.S. labeling): Oral: &ldquo;Pulse-dosing&rdquo;: 200 mg twice daily for 1 week; repeat 1-week course twice with 3-week off-time between each course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paracoccidioidomycosis:",
"     </b>",
"     Canadian labeling (not in U.S. labeling):  Oral: 100 mg once daily for 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Penicilliosis, HIV-positive (unlabeled use):",
"     </b>",
"     Oral: 400 mg daily for 8 weeks (mild disease) or 10 weeks (severe infections). In severely-ill patients, initiate therapy with 2 weeks of amphotericin B. Maintenance: 200 mg daily (CDC, 2009b)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pityriasis versicolor:",
"     </b>",
"     Canadian labeling (not in U.S. labeling): Oral: 200 mg once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pneumonia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Coccidioides:",
"     </i>",
"     Mild-to-moderate: 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Coccidioides, HIV-positive (focal pneumonia):",
"     </i>",
"     200 mg 3 times/day for 3 days, then 200 mg twice daily (CDC, 2009b)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sporotrichosis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Lymphocutaneous:",
"     </i>",
"     100-200 mg/day for 3-6 months (Kauffman,  2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Canadian labeling (not in U.S. labeling): 100 mg once daily for 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Osteoarticular and pulmonary:",
"     </i>",
"     200 mg twice daily for &ge;1 years (may use amphotericin B initially for stabilization) (Kauffman, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Tinea corporis or tinea cruris:",
"     </b>",
"     Canadian labeling (not in U.S. labeling): Oral: 100 mg once daily for 14 consecutive days or 200 mg once daily for 7 consecutive days.",
"     <b>",
"      Note:",
"     </b>",
"     Equivalency between regimens not established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Tinea pedis:",
"     </b>",
"     Canadian labeling (not in U.S. labeling): Oral: 100 mg once daily for 28 consecutive days or 200 mg twice daily for 7 consecutive days.",
"     <b>",
"      Note:",
"     </b>",
"     Equivalency between regimens not established. Patients with chronic resistant infection may benefit from lower dose and extended treatment time (100 mg once daily for 28 days).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F185447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/59/6074?source=see_link\">",
"      see \"Itraconazole: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Manufacturer labeling states that a small number of patients 3-16 years of age have been treated with 100 mg/day for systemic fungal infections with no serious adverse effects reported. A dose of 5 mg/kg once daily was used in a pharmacokinetic study using the oral solution in patients 6 months to 12 years; duration of study was 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Infants and Children (HIV-exposed/-positive; unlabeled use; CDC, 2009a):",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;200 mg daily should be administered in 2 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Candidiasis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Oropharyngeal:",
"     </i>",
"     Oral solution: 2.5 mg/kg/dose twice daily (maximum: 200 mg/day [400 mg/day if fluconazole-refractory]) for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Esophageal:",
"     </i>",
"     Oral solution: 5 mg/kg/day once daily or divided twice daily for 4-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Coccidioidomycosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     Oral: 5-10 mg/kg/dose twice daily for 3 days, followed by 2-5 mg/kg/dose orally twice daily (maximum: 400 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Relapse prevention:",
"     </i>",
"     Oral: 2-5 mg/kg/dose twice daily (maximum: 400 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cryptococcus:",
"     </b>",
"     <i>",
"      Relapse prevention:",
"     </i>",
"     Oral solution: 5 mg/kg/dose once daily (maximum: 200 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Histoplasmosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Treatment of mild disseminated disease",
"     </i>",
"     : Oral solution: 2-5 mg/kg/dose 3 times daily for 3 days (9 doses), followed by twice daily for 12 months (maximum: 200 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Consolidation treatment for moderate-severe to severe disseminated disease, including CNS infection (following appropriate induction therapy):",
"     </i>",
"     2-5 mg/kg/dose 3 times daily for 3 days, followed by 2-5 mg/kg/dose (maximum: 200 mg/dose) twice daily for 12 months for non-CNS-disseminated disease or for &ge;12 months for CNS infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Relapse prevention:",
"     </i>",
"     Oral solution: 5 mg/kg/dose twice daily (maximum: 400 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F185426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F185427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer's labeling states to use with caution in patients with renal impairment. Limited data suggests that no dosage adjustments are required in renal impairment; wide variations observed in plasma concentrations versus time profiles in patients with uremia, or receiving hemodialysis or continuous ambulatory peritoneal dialysis (Boelaert, 1988).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F185428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, use caution and monitor closely for signs/symptoms of toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sporanox&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sporanox&reg;: 10 mg/mL (150 mL) [contains propylene glycol; cherry-caramel flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onmel&trade;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15674161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onmel&trade; 200 mg tablets: FDA approved November 2012; availability anticipated January 2013. Onmel&trade; is indicated for the treatment of onychomycosis of the toenail; consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F185398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Doses &gt;200 mg/day are given in 2 divided doses; do not administer with antacids. Capsule and oral solution formulations are not bioequivalent and thus are not interchangeable. Capsule absorption is best if taken with food, therefore, it is best to administer itraconazole after meals; solution should be taken on an empty stomach. When treating oropharyngeal and esophageal candidiasis, solution should be swished vigorously in mouth (10 mL at a time), then swallowed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F185396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Oral capsules: Treatment of susceptible fungal infections in immunocompromised and immunocompetent patients including blastomycosis and histoplasmosis; indicated for aspergillosis (in patients intolerant/refractory to amphotericin B), and onychomycosis of the toenail and fingernail (in nonimmunocompromised patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: Treatment of oral and esophageal candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling: Oral capsules: Additional indications (not in U.S. labeling): Treatment of oral and esophageal candidiasis; treatment of cutaneous and lymphatic sporotrichosis, chromomycosis, or paracoccidioidomycosis in immunocompetent and immunosuppressed patients; treatment of onychomycosis in immunosuppressed patients; treatment of dermatomycoses due to tinea pedis, tinea cruris, tinea corporis and of pityriasis versicolor in immunocompetent and immunocompromised patients in whom oral therapy is appropriate",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Itraconazole may be confused with fluconazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sporanox&reg; may be confused with Suprax&reg;, Topamax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F185466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Nausea (3% to 11%), diarrhea (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (4%), hypertension (3%), chest pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4% to 10%), fever (2% to 7%), dizziness (2% to 4%), anxiety (3%), depression (2% to 3%), fatigue (2% to 3%), pain (2% to 3%), malaise (1% to 3%), dreams abnormal (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3% to 9%), pruritus (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia (&le;3%), hypokalemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (5% to 7%), abdominal pain (2% to 6%), dyspepsia (&le;4%), flatulence (&le;4%), gingivitis (3%), stomatitis (ulcerative) (&le;3%), constipation (2% to 3%), appetite increased (2%), gastritis (2%), gastroenteritis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: LFTs abnormal (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bursitis (3%), myalgia (&le;3%), tremor (2%), weakness (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Cystitis (3%), urinary tract infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (5% to 9%), upper respiratory tract infection (8%), sinusitis (2% to 7%), cough (4%), dyspnea (2%), pharyngitis (&le;2%), pneumonia (2%), sputum increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased (3%), herpes zoster (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Adrenal insufficiency, albuminuria, allergic reactions, alopecia, anaphylactoid reactions, anaphylaxis, angioedema, anorexia, arrhythmia, arthralgia, blurred vision, dehydration, diplopia, dysgeusia, dysphagia, erythema multiforme, exanthematous pustulosis, exfoliative dermatitis, gynecomastia, hearing loss, heart failure, hematuria, hepatic failure, hepatitis, hepatotoxicity, hot flashes, hypoesthesia, impotence, insomnia, leukocytoclastic dermatitis, leukopenia, libido decreased, menstrual disorders, neutropenia, pancreatitis, paresthesia, peripheral edema, photosensitivity, pollakiuria, pulmonary edema, rigors, serum sickness, somnolence, Stevens-Johnson syndrome, thrombocytopenia, taste perversion, tinnitus, toxic epidermal necrolysis, urinary incontinence, urticaria, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F185401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to itraconazole (use caution in patients with a history of hypersensitivity to other azoles), any component of the formulation; concurrent administration with cisapride, dofetilide, ergot derivatives, felodipine, levomethadyl, lovastatin, methadone, midazolam (oral), nisoldipine, pimozide, quinidine, simvastatin, or triazolam; treatment of onychomycosis (or other non-life-threatening indications) in patients with evidence of ventricular dysfunction, heart failure (HF) or a history of HF; treatment of onychomycosis in patients who are pregnant or intend on becoming pregnant",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Oral capsule: Additional contraindications (not in U.S. labeling): Concurrent administration with eletriptan; treatment of dermatomycosis (tinea pedis, tinea cruris, tinea corporis) and of pityriasis versicolor in patients who are pregnant or intend on becoming pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F185384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hearing loss: Transient or permanent hearing loss has been reported. Quinidine (a contraindicated drug) was used concurrently in several of these cases. Hearing loss usually resolves after discontinuation, but may persist in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure:",
"     <b>",
"      [U.S. Boxed Warning]: Negative inotropic effects have been observed following intravenous administration. Discontinue or reassess use if signs or symptoms of heart failure (HF) occur during treatment.",
"     </b>",
"     CHF has been reported, particularly in patients receiving a total daily oral dose of 400 mg. Use with caution in patients with risk factors for HF (COPD, renal failure, edematous disorders, ischemic or valvular disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Rare cases of serious hepatotoxicity (including liver failure and death) have been reported (including some cases occurring within the first week of therapy); hepatotoxicity was reported in some patients without pre-existing liver disease or risk factors. Use with caution in patients with pre-existing hepatic impairment; monitor liver function closely and dosage adjustment may be warranted. Not recommended for use in patients with active liver disease, elevated liver enzymes, or prior hepatotoxic reactions to other drugs unless the expected benefit exceeds the risk of hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropathy: Discontinue if signs or symptoms of neuropathy occurs during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cystic fibrosis: Large differences in itraconazole pharmacokinetic parameters have been observed in cystic fibrosis patients receiving the solution; if a patient with cystic fibrosis does not respond to therapy, alternate therapies should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Onychomycosis:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of onychomycosis in  patients with ventricular dysfunction or a history of HF.",
"     </b>",
"     Due to potential toxicity, the manufacturer recommends confirmation of diagnosis testing of nail specimens prior to treatment of onychomycosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; limited information is available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers (CCBs): May cause additive negative inotropic effects when used concurrently with itraconazole. Itraconazole may also inhibit the metabolism of CCBs. Therefore, use caution with concurrent use of itraconazole and CCBs due to an increased risk of heart failure.  Concurrent use of itraconazole and nisoldipine is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions:",
"     <b>",
"      [U.S. Boxed Warning]: Serious cardiovascular adverse events including, QT prolongation, ventricular tachycardia, torsade de pointes, cardiac arrest and/or sudden death have been observed due to itraconazole-induced increased serum concentrations of the following: Cisapride, dofetilide, ergot alkaloids (dihydroergotamine, ergonovine, ergotamine, methylergonovine), felodipine, levomethadyl, lovastatin, methadone, midazolam (oral), nisoldipine, pimozide, simvastatin, quinidine, or triazolam; concurrent use contraindicated.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral/esophageal candidiasis: Only the oral solution has proven efficacy; mucosal exposure may vary between the oral solution and capsules",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral solution: Initiation of treatment with oral solution is not recommended in patients at immediate risk for systemic candidiasis (eg, patients with severe neutropenia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability: Due to differences in bioavailability, oral capsules and oral solution",
"     <b>",
"      cannot be used interchangeably.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F185462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Itraconazole may increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Itraconazole. Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Itraconazole may increase the serum concentration of AtorvaSTATin.  Management: Limit atorvastatin to a maximum adult dose of 20 mg/day in patients receiving itraconazole.  Assess clinical response to ensure that the lowest necessary dose of atorvastatin is used. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: Itraconazole may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).  Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Quazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Boceprevir. Management: Limit maximum adult itraconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in itraconazole concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Itraconazole may increase the serum concentration of Cardiac Glycosides.  Management: Consider preemptive cardiac glycoside dose adjustments with initiation / changes / discontinuation of itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Cobicistat. Management: Limit itraconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Darunavir. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving darunavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Itraconazole may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Itraconazole may increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Itraconazole may increase the serum concentration of Elvitegravir.  Management: Limit itraconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Itraconazole may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Itraconazole may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Itraconazole may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Itraconazole may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eszopiclone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Eszopiclone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felodipine: Itraconazole may increase the serum concentration of Felodipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Itraconazole may increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Itraconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day itraconazole may also require dose reduction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This specifically applies to oral antifungal administration, and the interaction may be different depending on specific dosage form being used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Itraconazole. Management: When this combination is used, the itraconazole should be administered with a cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Indinavir. Management: Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with itraconazole.  Monitor for increased systemic effects (including adverse/toxic effects) of itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase the serum concentration of Itraconazole. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Itraconazole may increase the serum concentration of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Itraconazole may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Itraconazole may increase the serum concentration of Midazolam.  Management: Oral midazolam is contraindicated.  Use intravenous midazolam with great caution in patients receiving itraconazole, employing reduced initial doses whenever possible and monitoring closely for enhanced and prolonged effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paliperidone: Itraconazole may decrease the metabolism of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Itraconazole may increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine.  Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Repaglinide.  Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Itraconazole. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Itraconazole may increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Itraconazole may increase the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving saquinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Itraconazole may increase the serum concentration of Sildenafil.  Management: Concurrent itraconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Itraconazole may increase the serum concentration of Sirolimus.  Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Solifenacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of SUNItinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Itraconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with itraconazole. Tacrolimus dose reductions will likely be required. The magnitude of this interaction may be greater in older patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Itraconazole may increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Itraconazole may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Itraconazole.  Management: Doses of itraconazole greater than 200 mg/day are not recommended in patients receiving telaprevir.  Use extra caution when using these drugs in combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Itraconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus.  Management: Consider temsirolimus dose reductions or alternatives to itraconazole.  Monitor sirolimus concentrations in all patients receiving itraconazole or any systemic azole antifungal.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase the serum concentration of Itraconazole. Management: Limit itraconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Itraconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil dosing to a  maximum of 5 mg per 24 hours  in patients receiving itraconazole 200 mg/day, and a maximum of 2.5 mg per 24 hours in patients receiving itraconazole 400 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinBLAStine: Itraconazole may increase the serum concentration of VinBLAStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Itraconazole may enhance the adverse/toxic effect of VinCRIStine. Itraconazole may increase the serum concentration of VinCRIStine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vinorelbine: Itraconazole may enhance the adverse/toxic effect of Vinorelbine. Itraconazole may increase the serum concentration of Vinorelbine.  Management: Monitor for increased toxic effects of vinorelbine if itraconazole is being received/initiated/dose increased.  Decreased vinorelbine doses may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Itraconazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Zolpidem.  Management: Consider using a lower starting dose of zolpidem in patients receiving systemic azole antifungals. Monitor patients closely for increased magnitude and/or duration of zolpidem effects when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F185416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsules: Absorption enhanced by food and possibly by gastric acidity. Cola drinks have been shown to increase the absorption of the capsules in patients with achlorhydria or those taking H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonists or other gastric acid suppressors. Grapefruit/grapefruit juice may increase serum levels. Management: Take capsules immediately after meals. Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solution: Food decreases the bioavailability and increases the time to peak concentration. Management: Take solution on an empty stomach 1 hour before or 2 hours after meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease itraconazole levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F185391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F185405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose related adverse events were observed in animal reproduction studies. Use is contraindicated for the treatment of onychomycosis during pregnancy. If used for the treatment of onychomycosis in women of reproductive potential, effective contraception should be used during treatment and for 2 months following treatment. Therapy should begin on the second or third day following menses. Congenital abnormalities have been reported during postmarketing surveillance, but a causal relationship has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F185433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F185406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule: Take with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution: Take without food, if possible.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F185404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Itraconazole Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $278.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Sporanox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $576.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Sporanox Pulsepak Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (28): $539.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sporanox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (150 mL): $274.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Onmel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (14): $480.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F185393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function in patients with pre-existing hepatic dysfunction, and in all patients being treated for longer than 1 month; serum concentrations particularly for oral therapy (due to erratic bioavailability with capsule formulation); renal function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2523781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum concentrations may be performed to assure therapeutic levels. Itraconazole plus the metabolite hydroxyitraconazole concentrations should be &gt;1 mcg/mL (not to exceed 10 mcg/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timing of serum samples: Obtain level after ~2 weeks of therapy, level may be drawn anytime during the dosing interval.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F185407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Canadiol (ES);",
"     </li>",
"     <li>",
"      Candistat (IN);",
"     </li>",
"     <li>",
"      Canditral (PE, SG);",
"     </li>",
"     <li>",
"      Chme (TW);",
"     </li>",
"     <li>",
"      Fungitrazol (ID);",
"     </li>",
"     <li>",
"      Hantrazol (KP);",
"     </li>",
"     <li>",
"      Hitrazole (KP);",
"     </li>",
"     <li>",
"      Icomein (TW);",
"     </li>",
"     <li>",
"      Inox (HK, MY, PH);",
"     </li>",
"     <li>",
"      Irta (KP);",
"     </li>",
"     <li>",
"      Isox (DO, GT, HN, MX, PA, SV);",
"     </li>",
"     <li>",
"      Itcozol (NZ);",
"     </li>",
"     <li>",
"      Itra (TH);",
"     </li>",
"     <li>",
"      Itracon (HK, KP, SG, TH);",
"     </li>",
"     <li>",
"      Itrafung (EC);",
"     </li>",
"     <li>",
"      Itragen (CO);",
"     </li>",
"     <li>",
"      Itranax (MX);",
"     </li>",
"     <li>",
"      Itranol (IL);",
"     </li>",
"     <li>",
"      Itrasix (TH);",
"     </li>",
"     <li>",
"      Itraspor (TR);",
"     </li>",
"     <li>",
"      Itrazole (NZ);",
"     </li>",
"     <li>",
"      Itzol (ID);",
"     </li>",
"     <li>",
"      Konitra (KP);",
"     </li>",
"     <li>",
"      Micoral (PE);",
"     </li>",
"     <li>",
"      Mycotrazol (HK);",
"     </li>",
"     <li>",
"      Newtrazole (KP);",
"     </li>",
"     <li>",
"      Norspor (TH);",
"     </li>",
"     <li>",
"      Orungal (BG, EE, HR, HU, PL, RU);",
"     </li>",
"     <li>",
"      Quali-Itrazole (HK);",
"     </li>",
"     <li>",
"      Sempera (DE);",
"     </li>",
"     <li>",
"      Sinozol (MX);",
"     </li>",
"     <li>",
"      Spazol (TH);",
"     </li>",
"     <li>",
"      Sponex (KP);",
"     </li>",
"     <li>",
"      Sporacid (ID);",
"     </li>",
"     <li>",
"      Sporal (TH);",
"     </li>",
"     <li>",
"      Sporanox (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CY, CZ, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, ID, IE, IL, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PR, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Sporanox IV (HK, PH);",
"     </li>",
"     <li>",
"      Spornar (TH);",
"     </li>",
"     <li>",
"      Spotra (KP);",
"     </li>",
"     <li>",
"      Spyrocon (ID);",
"     </li>",
"     <li>",
"      Trachon (ID);",
"     </li>",
"     <li>",
"      Unitrac (SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F185383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with cytochrome P450 activity, decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting cell membrane formation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F185400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Requires gastric acidity; capsule better absorbed with food, solution better absorbed on empty stomach",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     (average): 796 &plusmn; 185 L or 10 L/kg; highly lipophilic and tissue concentrations are higher than plasma concentrations. The highest concentrations: adipose, omentum, endometrium, cervical and vaginal mucus, and skin/nails. Aqueous fluids (eg, CSF and urine) contain negligible amounts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 99.8%; metabolite hydroxy-itraconazole: 99.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP3A4 into &gt;30 metabolites including hydroxy-itraconazole (major metabolite); appears to have",
"     <i>",
"      in vitro",
"     </i>",
"     antifungal activity. Main metabolic pathway is oxidation; may undergo saturation metabolism with multiple dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Variable, ~55% (oral solution) in 1 small study;",
"     <b>",
"      Note:",
"     </b>",
"     Oral solution has a higher degree of bioavailability (149% &plusmn; 68%) relative to oral capsules; should not be interchanged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: Single dose: ~21 hours, steady state: 64 hours; Cirrhosis (single dose): 37 hours (range: 20-54 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Capsules: 3-5 hours; Oral solution: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;0.03% active drug, 40% as inactive metabolites); feces (~3% to 18%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahmad SR, Singer SJ, and Leissa BG, &ldquo;Congestive Heart Failure Associated With Itraconazole,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 357(9270):1766-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/11403818/pubmed\" id=\"11403818\" target=\"_blank\">",
"        11403818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Amichai B and Grunwald MH, &ldquo;Adverse Drug Reactions of the New Oral Antifungal Agents - Terbinafine, Fluconazole, and Itraconazole,&rdquo;",
"      <i>",
"       Int J Dermatol",
"      </i>",
"      , 1998, 37(6):410-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/9646122/pubmed\" id=\"9646122\" target=\"_blank\">",
"        9646122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boelaert J, Schurgers M, Matthys E, et al, &ldquo;Itraconazole Pharmacokinetics in Patients With Renal Dysfunction,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1988, 32(10):1595-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/2847635/pubmed\" id=\"2847635\" target=\"_blank\">",
"        2847635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009b, 58(4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman SW, Dismukes WE, Proia LA, et al, &ldquo;Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(12):1801-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/18462107/pubmed\" id=\"18462107\" target=\"_blank\">",
"        18462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cleary JD, Taylor JW, and Chapman SW, &ldquo;Itraconazole in Antifungal Therapy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992, 26(4):502-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/1315596/pubmed\" id=\"1315596\" target=\"_blank\">",
"        1315596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cowie F, Meller ST, Cushing P, et al, &ldquo;Chemoprophylaxis for Pulmonary Aspergillosis During Intensive Chemotherapy,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1994, 70(2):136-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/8129437/pubmed\" id=\"8129437\" target=\"_blank\">",
"        8129437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Backer M, De Vroey C, Lesaffre E, et al, &ldquo;Twelve Weeks of Continuous Oral Therapy for Toenail Onychomycosis Caused by Dermatophytes: A Double-Blind Comparative Trial of Terbinafine 250 mg/day Versus Itraconazole 200 mg/day,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1998, 38(5 Pt 3):S57-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/9594939/pubmed\" id=\"9594939\" target=\"_blank\">",
"        9594939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Denning DW, Lee JY, Hostetler JS, et al, &ldquo;NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1994, 97(2):135-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/8059779/pubmed\" id=\"8059779\" target=\"_blank\">",
"        8059779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galgiani JN, Ampel NM, Blair JE, et al, &ldquo;Coccidioidomycosis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(9):1217-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/16206093/pubmed\" id=\"16206093\" target=\"_blank\">",
"        16206093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grant SM and Clissold SP, &ldquo;Itraconazole. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Superficial and Systemic Mycoses,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1989, 37(3):310-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/2540949/pubmed\" id=\"2540949\" target=\"_blank\">",
"        2540949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haria M, Bryson HM, and Goa KL, &ldquo;Itraconazole: A Reappraisal of Its Pharmacological Properties and Therapeutic Use in the Management of Superficial Fungal Infections,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 51(4):585-620.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/8706596/pubmed\" id=\"8706596\" target=\"_blank\">",
"        8706596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heymann WR and Manders SM, &ldquo;Itraconazole-Induced Acute Generalized Exanthemic Pustulosis,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1995, 33(1):130-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/7601931/pubmed\" id=\"7601931\" target=\"_blank\">",
"        7601931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jennings TS and Hardin TC, &ldquo;Treatment of Aspergillosis With Itraconazole,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1993, 27(10):1206-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/8251691/pubmed\" id=\"8251691\" target=\"_blank\">",
"        8251691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman CA, Bustamante B, Chapman SW, et al, \"Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(10):1255-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/17968818/pubmed\" id=\"17968818\" target=\"_blank\">",
"        17968818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE, Rollins CJ, Yee WJ, et al, &ldquo;Low Itraconazole Serum Concentrations Following Administration of Itraconazole Suspension to Critically Ill Allogenic Bone Marrow Transplant Recipients,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(2):140-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/7756712/pubmed\" id=\"7756712\" target=\"_blank\">",
"        7756712",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohr J, Johnson M, Cooper T, et al, &ldquo;Current Options in Antifungal Pharmacotherapy,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2008, 28(5):614-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/18447660/pubmed\" id=\"18447660\" target=\"_blank\">",
"        18447660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neuvonen PJ, Backman JT, and Niemi M, &ldquo;Pharmacokinetic Comparison of the Potential Over-The-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin,&rdquo;",
"      <i>",
"       Clin Pharmacokinet,",
"      </i>",
"      2008, 47(7):463-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/18563955/pubmed\" id=\"18563955\" target=\"_blank\">",
"        18563955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Terrell CL, &ldquo;Antifungal Agents. Part II. The Azoles,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(1):78-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/9987539/pubmed\" id=\"9987539\" target=\"_blank\">",
"        9987539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobon AM, Franco L, Espinal D, et al, &ldquo;Disseminated Histoplasmosis in Children: The Role of Itraconazole Therapy,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1996; 15:1002-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trepanier EF and Amsden GW, &ldquo;Current Issues in Onchomycosis,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1998, 32(2):204-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/9496407/pubmed\" id=\"9496407\" target=\"_blank\">",
"        9496407",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tucker RM, Haq Y, Denning DW, et al, &ldquo;Adverse Effects Associated With Itraconazole in 189 Patients on Chronic Therapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1990, 26(4):561-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/2174854/pubmed\" id=\"2174854\" target=\"_blank\">",
"        2174854",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al, &ldquo;Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(3):327-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/18177225/pubmed\" id=\"18177225\" target=\"_blank\">",
"        18177225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheat J, Freifeld AG, Kleiman MB, et al, &ldquo;Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(7):807&ndash;25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/17806045/pubmed\" id=\"17806045\" target=\"_blank\">",
"        17806045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheat J, Hafner R, Korzun AH, et al, &ldquo;Itraconazole Treatment of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1995, 98(4):336-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/15/20730/abstract-text/7709945/pubmed\" id=\"7709945\" target=\"_blank\">",
"        7709945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8586 Version 53.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20730=[""].join("\n");
var outline_f20_15_20730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708958\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185420\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185421\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185468\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185425\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185447\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185426\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185427\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185428\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185395\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185380\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15674161\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185398\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185396\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185476\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185466\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185401\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185384\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185462\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185389\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185416\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185391\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185405\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185433\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185406\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185404\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185393\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523781\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185407\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185383\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185400\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8586\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8586|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/17/34069?source=related_link\">",
"      Itraconazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/59/6074?source=related_link\">",
"      Itraconazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_15_20731="Survival in LM patients";
var content_f20_15_20731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival in patients with leptomeningeal metastases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"1\">",
"        Median survival, months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Untreated",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Treated, non-responding",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Primary tumor histology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Melanoma",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-small cell lung",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AIDS-related lymphoma",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-AIDS-related lymphoma",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with data from: Chamberlain MC. Leptomeningeal metastases: A review of evaluation and treatment. Journal of Neuro-Oncology 1998;37(3):271-284.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20731=[""].join("\n");
var outline_f20_15_20731=null;
var title_f20_15_20732="Plaques";
var content_f20_15_20732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of plaques",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Acanthosis nigricans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Candidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cellulitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Deep fungal infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dermatomyositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diaper dermatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eczematous dermatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythrasma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tinea infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Granuloma annulare",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ichthyosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lichen planus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lichen sclerosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lyme disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Lymphoma (cutaneous T cell)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Morphea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myxedema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Necrobiosis lipoidica diabeticorum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paget's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pityriasis rosea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psoriasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Seborrheic dermatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sweet's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tinea versicolor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Xanthelasma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20732=[""].join("\n");
var outline_f20_15_20732=null;
var title_f20_15_20733="Card synd X variant angina";
var content_f20_15_20733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of variant angina and cardiac syndrome X",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Variant (also known as vasospastic or Prinzmetal) angina (see \"Variant angina\")",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cardiac syndrome X (see \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Definition",
"        </strong>",
"       </td>",
"       <td>",
"        Spontaneous episodes of angina in association with ST segment elevation on the electrocardiogram (ECG)",
"       </td>",
"       <td>",
"        Exertional angina associated with ST segment depression on treadmill exercise testing and normal coronary angiography without demonstrable vasospasm",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Demography",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        Patients more likely younger or female than those with epicardial CAD",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Clinical characteristics",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Chest pain episodes often occur at rest; often predominant in the morning. Sometimes exercise-induced, especially if epicardial CAD is present.",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Chest pain episodes often occur with exertion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        50 percent \"typical\" angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Duration often &gt;10 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest pain typically associated with ST-segment elevation",
"       </td>",
"       <td>",
"        Chest pain associated with ST-segment depression on the ECG",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Pathogeneses",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Usually epicardial disease, near proximal plaque",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Ischemia due to microvascular disease in approximately 30 percent of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Association with cocaine or Raynaud syndrome",
"       </td>",
"       <td rowspan=\"2\">",
"        Enhanced pain sensitivity (\"sensitive heart\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microvascular disease with normal epicardial vessels",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Diagnostic evaluation",
"        </strong>",
"       </td>",
"       <td>",
"        History: chest pain more likely rest than exertional",
"       </td>",
"       <td>",
"        History: chest pain exertional with atypical characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ECG: ST segment elevation",
"       </td>",
"       <td>",
"        ECG: normal or ST segment depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stress testing: often normal, except when epicardial disease present",
"       </td>",
"       <td>",
"        Stress testing: ST segment depression; myocardial perfusion defects may or may not be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary angiography: often proximal plaque. Provocative testing may be abnormal.",
"       </td>",
"       <td>",
"        Coronary angiography: normal epicardial vessels; no vasospasm; coronary flow reserve can be assessed to determine posible microvascular disease",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        <strong>",
"         Treatment",
"        </strong>",
"       </td>",
"       <td>",
"        Coronary risk factor modification",
"       </td>",
"       <td>",
"        Reassurance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blockers",
"       </td>",
"       <td>",
"        Pain relief",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitroglycerin",
"       </td>",
"       <td>",
"        Beta adrenergic blockade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Contraindicated therapies:",
"       </td>",
"       <td class=\"sublist_other_start\" rowspan=\"3\">",
"        Benefit from calcium channel blockade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sumatriptan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Relative contraindication may include beta blockade (&rarr; vasospasm?), aspirin (prostacyclin inhibition)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Prognosis",
"        </strong>",
"       </td>",
"       <td>",
"        Without epicardial disease, good (&gt;95 percent overall survival at five years)",
"       </td>",
"       <td>",
"        CASS registry: seven-year survival rate was 96 percent in those with normal arteriograms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Worse with:",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Worse:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Epicardial disease",
"       </td>",
"       <td class=\"sublist1\">",
"        In some women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Arrhythmic complication (especially VF or sudden cardiac death) during symptoms",
"       </td>",
"       <td class=\"sublist1\">",
"        Non-ST elevation ACS",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim L Meisel, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20733=[""].join("\n");
var outline_f20_15_20733=null;
var title_f20_15_20734="Gram stain sputum 10";
var content_f20_15_20734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain sputum 10",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20734=[""].join("\n");
var outline_f20_15_20734=null;
var title_f20_15_20735="BRAO platelet fibrin embolu";
var content_f20_15_20735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    BRAO platelet fibrin embolus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 156px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Platelet-fibrin material in a branch retinal artery. B) The platelet-fibrin material seen in figure A has moved distally after several seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_15_20735=[""].join("\n");
var outline_f20_15_20735=null;
